Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:3908
Name lung non-small cell carcinoma
Definition A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA act mut Pictilisib lung non-small cell carcinoma sensitive detail...
PTEN del PF-04691502 lung non-small cell carcinoma predicted - sensitive detail...
PTEN loss Pictilisib lung non-small cell carcinoma sensitive detail...
BRAF Y472C Dasatinib lung non-small cell carcinoma sensitive detail...
BRAF G466V Dasatinib lung non-small cell carcinoma sensitive detail...
BRAF V600E Vemurafenib lung non-small cell carcinoma sensitive detail...
BRAF V600E Dabrafenib lung non-small cell carcinoma sensitive detail...
TP53 P72R Cisplatin + Irinotecan lung non-small cell carcinoma sensitive detail...
ALK fusion ALK S1206Y Crizotinib lung non-small cell carcinoma predicted - resistant detail...
PIK3CA E545K Copanlisib + Paclitaxel lung non-small cell carcinoma sensitive detail...
RET act mut Ponatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Belizatinib lung non-small cell carcinoma no benefit detail...
ALK positive Ensartinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1269A Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK G1269A Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Ensartinib + Sirolimus lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1202R Ceritinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK V1180L Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Lorlatinib lung non-small cell carcinoma sensitive detail...
PIK3CA mutant PWT33597 lung non-small cell carcinoma sensitive detail...
ALK rearrange Crizotinib lung non-small cell carcinoma sensitive detail...
CDKN2A loss Palbociclib lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion Alectinib lung non-small cell carcinoma sensitive detail...
ALK fusion Brigatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Brigatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Ceritinib lung non-small cell carcinoma conflicting detail...
NRAS Q61K Gedatolisib lung non-small cell carcinoma decreased response detail...
TP53 R158G Gedatolisib lung non-small cell carcinoma sensitive detail...
STK11 mutant Gedatolisib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1269A Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171T Lorlatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Ceritinib + Crizotinib lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK mut Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK V1180L Alectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK V1180L Crizotinib lung non-small cell carcinoma resistant detail...
ALK rearrange Ceritinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Brigatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Alectinib lung non-small cell carcinoma sensitive detail...
ALK rearrange Ensartinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK TAE226 lung non-small cell carcinoma sensitive detail...
BRAF G469A TAE226 lung non-small cell carcinoma sensitive detail...
BRAF G466V TAE226 lung non-small cell carcinoma sensitive detail...
FGFR1 amp Zoligratinib lung non-small cell carcinoma sensitive detail...
TP53 R248W APR-246 + Cisplatin lung non-small cell carcinoma sensitive detail...
TP53 R273H APR-246 + Cisplatin lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1269A Alectinib lung non-small cell carcinoma sensitive detail...
BRAF V600E Navitoclax + Vemurafenib lung non-small cell carcinoma sensitive detail...
BRAF V600E Navitoclax + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF V600E Trametinib + TW-37 lung non-small cell carcinoma sensitive detail...
BRAF V600E TW-37 + Vemurafenib lung non-small cell carcinoma sensitive detail...
TP53 wild-type CEP-8983 + Cisplatin lung non-small cell carcinoma sensitive detail...
TP53 mutant CEP-8983 + Cisplatin lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY LY3009120 lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY Trametinib lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY Dabrafenib lung non-small cell carcinoma resistant detail...
ROS1 rearrange Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171S Alectinib lung non-small cell carcinoma predicted - resistant detail...
ATM loss Ceralasertib + Cisplatin lung non-small cell carcinoma sensitive detail...
EML4 - ALK Entrectinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK C1156Y Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Luminespib lung non-small cell carcinoma no benefit detail...
EML4 - ALK ALK C1156Y ALK L1198F Lorlatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK C1156Y ALK L1198F Crizotinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Alectinib lung non-small cell carcinoma sensitive detail...
ALK fusion Lorlatinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion Lorlatinib lung non-small cell carcinoma sensitive detail...
ALK fusion ALK G1202R Lorlatinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp Fexagratinib lung non-small cell carcinoma sensitive detail...
RET fusion Vandetanib lung non-small cell carcinoma sensitive detail...
ROS1 rearrange ALK neg Crizotinib lung non-small cell carcinoma sensitive detail...
ALK mutant Crizotinib + Onalespib lung non-small cell carcinoma no benefit detail...
CD274 positive Pembrolizumab lung non-small cell carcinoma sensitive detail...
BRAF L485Y GDC0879 lung non-small cell carcinoma resistant detail...
BRAF wild-type GDC0879 lung non-small cell carcinoma resistant detail...
BRAF L597V NRAS Q61K AZ628 lung non-small cell carcinoma sensitive detail...
BRAF L597V NRAS Q61K TAK-632 lung non-small cell carcinoma sensitive detail...
BRAF G466V TAK-632 lung non-small cell carcinoma sensitive detail...
BRAF L597V NRAS Q61K PLX7904 lung non-small cell carcinoma decreased response detail...
BRAF L597V NRAS Q61K Vemurafenib lung non-small cell carcinoma decreased response detail...
BRAF G466V Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF L597V NRAS Q61K Dabrafenib lung non-small cell carcinoma decreased response detail...
TP53 wild-type KRT-232 lung non-small cell carcinoma sensitive detail...
TP53 wild-type Cisplatin + KRT-232 lung non-small cell carcinoma sensitive detail...
TP53 wild-type Carboplatin + KRT-232 lung non-small cell carcinoma sensitive detail...
NRAS Q61K Pimasertib lung non-small cell carcinoma sensitive detail...
NRAS Q61K Everolimus + Pimasertib lung non-small cell carcinoma sensitive detail...
NRAS Q61K Pimasertib + Sorafenib lung non-small cell carcinoma sensitive detail...
NRAS Q61K Pimasertib + Regorafenib lung non-small cell carcinoma sensitive detail...
PIK3CA mutant PF-04691502 lung non-small cell carcinoma sensitive detail...
FGFR1 amp PRN1371 lung non-small cell carcinoma sensitive detail...
FGFR2 amp PRN1371 lung non-small cell carcinoma sensitive detail...
FGFR3 amp PRN1371 lung non-small cell carcinoma sensitive detail...
ALK rearrange Nivolumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Pembrolizumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Durvalumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Atezolizumab lung non-small cell carcinoma no benefit detail...
FGFR1 amp RO4987655 lung non-small cell carcinoma no benefit detail...
FGFR1 amp RO5126766 lung non-small cell carcinoma no benefit detail...
FGFR1 amp Selumetinib lung non-small cell carcinoma no benefit detail...
ALK rearrange ALK E1210K Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange MAP2K1 K57N Ceritinib + Selumetinib lung non-small cell carcinoma sensitive detail...
PIK3CA G118D LY3023414 lung non-small cell carcinoma sensitive detail...
EML4 - ALK Afatinib + Alectinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp E7090 lung non-small cell carcinoma sensitive detail...
FGFR1 amp NGI-1 lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK Brigatinib lung non-small cell carcinoma sensitive detail...
BRAF G469A Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF mutant Dabrafenib + Trametinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF G469V Sorafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF G469A Vemurafenib lung non-small cell carcinoma resistant detail...
BRAF G469A Trametinib lung non-small cell carcinoma sensitive detail...
BRAF G469A Trametinib + Vemurafenib lung non-small cell carcinoma conflicting detail...
ROS1 rearrange NPS-1034 lung non-small cell carcinoma sensitive detail...
STK11 inact mut Trametinib lung non-small cell carcinoma sensitive detail...
STK11 Q37* Trametinib lung non-small cell carcinoma sensitive detail...
STK11 E199* Trametinib lung non-small cell carcinoma sensitive detail...
STK11 W332* Trametinib lung non-small cell carcinoma sensitive detail...
STK11 dec exp Trametinib lung non-small cell carcinoma sensitive detail...
STK11 K48fs Trametinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion Taletrectinib lung non-small cell carcinoma predicted - sensitive detail...
ALK positive Entrectinib lung non-small cell carcinoma sensitive detail...
RET rearrange Alectinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK I1171N Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK G1202R Alectinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 rearrange Entrectinib lung non-small cell carcinoma sensitive detail...
STK11 E57fs Trametinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK F1245C Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK F1245C Ceritinib lung non-small cell carcinoma sensitive detail...
RET rearrange Cabozantinib lung non-small cell carcinoma sensitive detail...
RET rearrange Vandetanib lung non-small cell carcinoma sensitive detail...
RET rearrange Sunitinib lung non-small cell carcinoma predicted - sensitive detail...
RET rearrange RXDX-105 lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
TP53 mutant Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
ROS1 rearrange Ceritinib lung non-small cell carcinoma sensitive detail...
PIK3CA H1047X Taselisib lung non-small cell carcinoma sensitive detail...
FGFR1 amp GSK3052230 lung non-small cell carcinoma sensitive detail...
BRAF G466V Trametinib lung non-small cell carcinoma sensitive detail...
BRAF G466V NRAS Q61K Trametinib lung non-small cell carcinoma sensitive detail...
BRAF mutant KO-947 lung non-small cell carcinoma predicted - sensitive detail...
BRAF G466V Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
TP53 negative Seliciclib lung non-small cell carcinoma decreased response detail...
TP53 R175H Seliciclib lung non-small cell carcinoma resistant detail...
TP53 S215G Seliciclib lung non-small cell carcinoma resistant detail...
TP53 Y220C Seliciclib lung non-small cell carcinoma resistant detail...
TP53 P98A Seliciclib lung non-small cell carcinoma decreased response detail...
TP53 A159V Seliciclib lung non-small cell carcinoma decreased response detail...
TP53 Y234C Seliciclib lung non-small cell carcinoma decreased response detail...
TP53 wild-type Seliciclib lung non-small cell carcinoma sensitive detail...
NRAS mutant KO-947 lung non-small cell carcinoma predicted - sensitive detail...
STK11 mutant unspecified PD-1 antibody lung non-small cell carcinoma decreased response detail...
BRAF mutant unspecified PD-1 antibody lung non-small cell carcinoma predicted - sensitive detail...
FGFR1 amp NRAS amp Infigratinib lung non-small cell carcinoma resistant detail...
FGFR1 amp NRAS amp Trametinib lung non-small cell carcinoma resistant detail...
FGFR1 amp NRAS amp Infigratinib + Trametinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp NRAS over exp Infigratinib lung non-small cell carcinoma decreased response detail...
FGFR1 amp NRAS over exp Infigratinib + Trametinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp Infigratinib lung non-small cell carcinoma sensitive detail...
FGFR1 amp Infigratinib + Trametinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Crizotinib + Filgotinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK F1174V Alectinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171S ALK F1174V Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange Lorlatinib lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171T Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK I1171N Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK F1174V Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK L1152R Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK L1196M ALK G1269A Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK T1151dup ALK G1269A Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK amp Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK G1202R Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK CEP-28122 lung non-small cell carcinoma sensitive detail...
ALK negative CEP-28122 lung non-small cell carcinoma resistant detail...
ALK rearrange ALK L1196M Crizotinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK S1206Y Crizotinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK C1156Y Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 rearrange Alectinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Erlotinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Gefitinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Afatinib lung non-small cell carcinoma no benefit detail...
ALK rearrange Osimertinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Erlotinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Gefitinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Afatinib lung non-small cell carcinoma no benefit detail...
ROS1 rearrange Osimertinib lung non-small cell carcinoma no benefit detail...
EML4 - ALK ALK F1174V ALK G1202R Ceritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK F1174C Ceritinib lung non-small cell carcinoma resistant detail...
CD274 pos STK11 mut unspecified PD-1 antibody lung non-small cell carcinoma predicted - resistant detail...
BRAF act mut RAF709 lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK I1171N ALK L1198F Lorlatinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK I1171N ALK D1203N Lorlatinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK C1156Y ALK L1198F Lorlatinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK L1196M ALK G1202R Lorlatinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK G1202R ALK L1204V ALK G1269A Lorlatinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK D1203N ALK E1210K ALK G1269A Lorlatinib lung non-small cell carcinoma resistant detail...
RET fusion Selpercatinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion ROS1 L1951R ROS1 L2026M Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 fusion ROS1 L1951R ROS1 L2026M Ceritinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK E1210K Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK S1206C ALK E1210K Brigatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK F1174L ALK L1198V Brigatinib lung non-small cell carcinoma resistant detail...
ROS1 fusion KIT D816G Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK FGFR1 amp Brigatinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK HRAS amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
BRAF G469A Encorafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF G469A Dabrafenib lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK G1202R Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171N Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK I1171T Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK V1180L Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK V1180L Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171T Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK V1180L ALK L1196M ALK G1202R Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK D1203N Brigatinib lung non-small cell carcinoma predicted - resistant detail...
KEAP1 mutant Radiotherapy lung non-small cell carcinoma predicted - resistant detail...
BRAF D594N RMC-4550 lung non-small cell carcinoma predicted - sensitive detail...
BRAF N581D RMC-4550 lung non-small cell carcinoma predicted - sensitive detail...
RET rearrange Ponatinib lung non-small cell carcinoma no benefit detail...
FGFR1 V561M Fexagratinib lung non-small cell carcinoma resistant detail...
ALK rearrange TP53 mut Crizotinib lung non-small cell carcinoma decreased response detail...
ALK rearrange TP53 mut Ceritinib lung non-small cell carcinoma decreased response detail...
ALK rearrange TP53 mut Alectinib lung non-small cell carcinoma decreased response detail...
ALK rearrange TP53 mut Brigatinib lung non-small cell carcinoma decreased response detail...
STK11 mutant unspecified PD-L1 antibody lung non-small cell carcinoma decreased response detail...
BRAF mutant unspecified PD-L1 antibody lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK G1202R ALK G1269A Lorlatinib lung non-small cell carcinoma resistant detail...
CDKN2A negative Palbociclib lung non-small cell carcinoma predicted - sensitive detail...
CDKN2A negative Everolimus + Palbociclib lung non-small cell carcinoma sensitive detail...
CDKN2A negative Palbociclib + Sirolimus lung non-small cell carcinoma sensitive detail...
CDKN2A negative Palbociclib + PF-04691502 lung non-small cell carcinoma sensitive detail...
ALK fusion ALK G1202R KIT amp Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK Iruplinalkib lung non-small cell carcinoma sensitive detail...
BRAF V600X Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF V600E/K Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
BRAF V600K Dabrafenib + Trametinib lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Brigatinib lung non-small cell carcinoma no benefit detail...
CDKN2A inact mut Palbociclib lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion Crizotinib lung non-small cell carcinoma sensitive detail...
ALK fusion Ceritinib lung non-small cell carcinoma sensitive detail...
ROS1 fusion Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK MTI-31 lung non-small cell carcinoma sensitive detail...
ROS1 rearrange TP53 mut Crizotinib lung non-small cell carcinoma predicted - sensitive detail...
ROS1 rearrange PIK3CA E545K Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 rearrange ROS1 L2026M TP53 P278H Crizotinib lung non-small cell carcinoma predicted - resistant detail...
CD274 over exp Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Atezolizumab lung non-small cell carcinoma sensitive detail...
CD274 over exp Nivolumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Ipilimumab lung non-small cell carcinoma predicted - sensitive detail...
TP53 mutant Nivolumab lung non-small cell carcinoma predicted - sensitive detail...
TP53 mutant Ipilimumab + Nivolumab lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK G1202R Ceritinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK G1202R Ensartinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171X Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171X Ceritinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171X Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171X Ensartinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK L1196M Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK L1196M Ceritinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK L1196M Brigatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK L1196M Ensartinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK L1196M Lorlatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK G1202R Lorlatinib lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK D1203N Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174C Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174L Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171X Lorlatinib lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion Entrectinib lung non-small cell carcinoma sensitive detail...
CD274 positive SL-279252 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK E1303K Crizotinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion Ensartinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Ensartinib lung non-small cell carcinoma sensitive detail...
ALK rearrange PLB1003 lung non-small cell carcinoma predicted - sensitive detail...
ATM del AZD7648 + Olaparib lung non-small cell carcinoma sensitive detail...
ATM del AZD7648 lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK F1174C ALK G1202R Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174L ALK G1202R Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK T1151M ALK G1202R Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
CD274 positive Nivolumab lung non-small cell carcinoma no benefit detail...
ALK rearrange Crizotinib + Onalespib lung non-small cell carcinoma no benefit detail...
ALK C1156Y ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK F1174V ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK F1174L ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1196M ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK G1202R ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK I1171T ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK I1171S ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1152R ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK amp ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1152V ALK pos Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
FGFR1 amp Zotatifin lung non-small cell carcinoma sensitive detail...
ATM del Olaparib lung non-small cell carcinoma sensitive detail...
CD274 positive Atezolizumab + Carboplatin + Nab-paclitaxel lung non-small cell carcinoma sensitive detail...
BRAF V600X Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600D Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600M Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600K Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF N581S Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF K601E Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF K601N Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF G466A Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF G469V Vemurafenib lung non-small cell carcinoma no benefit detail...
BRAF G596R Vemurafenib lung non-small cell carcinoma no benefit detail...
TP53 R175H SLMP53-2 lung non-small cell carcinoma sensitive detail...
TP53 Y220C SLMP53-2 lung non-small cell carcinoma sensitive detail...
TP53 G245S SLMP53-2 lung non-small cell carcinoma sensitive detail...
PIK3CA mutant Sulindac lung non-small cell carcinoma predicted - sensitive detail...
PIK3CA act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
PTEN inact mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
NRAS act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
BRAF act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 act mut Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 S37F Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 S37C Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 D32V Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 G34V Osimertinib lung non-small cell carcinoma predicted - resistant detail...
CTNNB1 T41I Osimertinib lung non-small cell carcinoma predicted - resistant detail...
TP53 mutant Osimertinib lung non-small cell carcinoma not predictive detail...
TP53 inact mut Osimertinib lung non-small cell carcinoma not predictive detail...
ARID1A mutant unspecified PD-L1 antibody lung non-small cell carcinoma predicted - sensitive detail...
ARID1A mutant unspecified PD-1 antibody lung non-small cell carcinoma predicted - sensitive detail...
PIK3CA amp Sulindac lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Atezolizumab + Tiragolumab lung non-small cell carcinoma predicted - sensitive detail...
RET fusion Pralsetinib lung non-small cell carcinoma sensitive detail...
RET rearrange Selpercatinib lung non-small cell carcinoma sensitive detail...
CD274 positive Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Cisplatin + Pembrolizumab + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Carboplatin + Pembrolizumab + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Taletrectinib lung non-small cell carcinoma predicted - sensitive detail...
ALK mutant Belizatinib lung non-small cell carcinoma no benefit detail...
ALK amp Belizatinib lung non-small cell carcinoma no benefit detail...
STK11 loss Vistusertib lung non-small cell carcinoma no benefit detail...
FGFR2 V514L Fexagratinib lung non-small cell carcinoma no benefit detail...
FGFR3 P573S Fexagratinib lung non-small cell carcinoma no benefit detail...
FGFR3 S756P Fexagratinib lung non-small cell carcinoma no benefit detail...
CD274 positive Nivolumab + Pegilodecakin lung non-small cell carcinoma predicted - sensitive detail...
CD274 amp Nivolumab lung non-small cell carcinoma predicted - sensitive detail...
RET rearrange Pralsetinib lung non-small cell carcinoma sensitive detail...
ARID1A inact mut unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
PIK3CA E545K T-2143 lung non-small cell carcinoma sensitive detail...
BRAF G596V Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
NRAS Q61K BI-3406 lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK L1196Q Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK L1196Q Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E Pembrolizumab lung non-small cell carcinoma not predictive detail...
BRAF V600E Nivolumab lung non-small cell carcinoma not predictive detail...
BRAF mut CD274 pos Pembrolizumab lung non-small cell carcinoma not predictive detail...
BRAF mut CD274 pos Nivolumab lung non-small cell carcinoma not predictive detail...
BRAF mut CD274 pos Atezolizumab lung non-small cell carcinoma not predictive detail...
BRAF V600E Atezolizumab lung non-small cell carcinoma not predictive detail...
BRAF mutant unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
BRAF amp unspecified immune checkpoint inhibitor lung non-small cell carcinoma not predictive detail...
BRAF V600E unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
RET fusion unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
ROS1 fusion unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
RET mutant unspecified immune checkpoint inhibitor lung non-small cell carcinoma unknown detail...
ALK positive Lorlatinib lung non-small cell carcinoma sensitive detail...
KEAP1 dec exp Radiotherapy + Telaglenastat lung non-small cell carcinoma sensitive detail...
BRAF V600E FGFR2 A553D Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E PIK3CA E545K Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Cemiplimab lung non-small cell carcinoma sensitive detail...
ALK rearrange Ipilimumab + Nivolumab lung non-small cell carcinoma no benefit detail...
EML4 - ALK ALK I1171N Gilteritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171N Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK I1171N Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK I1171N Entrectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Gilteritinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK TP53 Q331* Alectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK TP53 Q331* Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK TP53 V274fs Alectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK TP53 V274fs Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK TP53 Q331* Alectinib + Ixazomib lung non-small cell carcinoma sensitive detail...
EML4 - ALK TP53 V274fs Alectinib + Ixazomib lung non-small cell carcinoma sensitive detail...
CD274 dec exp Avelumab + Pepinemab lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Durvalumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Retifanlimab lung non-small cell carcinoma predicted - sensitive detail...
TP53 Q331* AZ32 + Radiotherapy lung non-small cell carcinoma sensitive detail...
EML4 - ALK Alectinib + SHP099 lung non-small cell carcinoma sensitive detail...
EML4 - ALK Alectinib + Selumetinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Alectinib + RMC-4550 lung non-small cell carcinoma sensitive detail...
ALK fusion ALK T1151dup Ceritinib lung non-small cell carcinoma no benefit detail...
ALK fusion ALK T1151dup Lorlatinib lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Ipilimumab + Nivolumab lung non-small cell carcinoma sensitive detail...
KEAP1 D236H Gefitinib lung non-small cell carcinoma resistant detail...
KEAP1 D236H Afatinib lung non-small cell carcinoma resistant detail...
KEAP1 D236H Osimertinib lung non-small cell carcinoma resistant detail...
CDKN2A inact mut unspecified immune checkpoint inhibitor lung non-small cell carcinoma not predictive detail...
CDKN2A del unspecified immune checkpoint inhibitor lung non-small cell carcinoma not predictive detail...
CD274 positive Anlotinib + Cadonilimab lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Atezolizumab lung non-small cell carcinoma sensitive detail...
CD274 positive Durvalumab + Vactosertib lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion ROS1 S1986F ROS1 L2000V Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
CD274 over exp Niraparib + Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Niraparib + Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
ROS1 rearrange Repotrectinib lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK G1202del Lorlatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK F1174X Lorlatinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK G1269A Lorlatinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK XMU-MP-5 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y ALK L1196M ALK G1202R Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ROS1 rearrange Crizotinib lung non-small cell carcinoma predicted - sensitive detail...
NRAS Q61K Lifirafenib + PD-0325901 lung non-small cell carcinoma sensitive detail...
NRAS Q61K Lifirafenib + Pimasertib lung non-small cell carcinoma sensitive detail...
ALK rearrange Iruplinalkib lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Iruplinalkib lung non-small cell carcinoma sensitive detail...
ALK rearrange Ceritinib + Ribociclib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK G1202R Ceritinib + HJC0152 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1202R HJC0152 lung non-small cell carcinoma sensitive detail...
FGFR1 amp CPL304110 lung non-small cell carcinoma sensitive detail...
BRAF V600E LTT462 + LXH 254 lung non-small cell carcinoma predicted - sensitive detail...
BRAF K601N LTT462 + LXH 254 lung non-small cell carcinoma predicted - sensitive detail...
BRAF G466A LTT462 + LXH 254 lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange Foritinib lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion ALK C1156Y ALK L1198F Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion ALK L1196M ALK G1202R Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion ALK G1202R ALK L1204V ALK G1269A Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion ALK D1203N ALK E1210K ALK G1269A Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ALK fusion ALK G1202R ALK S1206F ALK G1269A Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
ROS1 fusion ROS1 G2032R Taletrectinib lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion TQ-B3139 lung non-small cell carcinoma sensitive detail...
EML4 - ALK TQ-B3139 lung non-small cell carcinoma sensitive detail...
CD274 positive MT-6402 lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK APG-2449 lung non-small cell carcinoma sensitive detail...
ALK rearrange ALK L1196Q Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK E1129V Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK amp Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK I1171S Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174L Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174V Alectinib lung non-small cell carcinoma predicted - resistant detail...
ALK rearrange ALK F1174S Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK E1129V Ceritinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171T ALK F1174V Ceritinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E BRAF K601_W604del Dabrafenib + Trametinib lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion APG-2449 lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion NUV-520 lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion ROS1 G2032R NUV-520 lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange Conteltinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M ALK G1202R NVL-655 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK T1151M ALK G1202R NVL-655 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1202R NVL-655 lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Cetrelimab lung non-small cell carcinoma predicted - sensitive detail...
ALK positive Brigatinib lung non-small cell carcinoma no benefit detail...
ALK V1180L Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK V1180Y Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
EML4 - ALK ALK I1171T ALK G1269A Brigatinib lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Carboplatin + Cemiplimab + Paclitaxel lung non-small cell carcinoma sensitive detail...
CD274 positive Cemiplimab + Cisplatin + Paclitaxel lung non-small cell carcinoma sensitive detail...
CD274 positive Carboplatin + Cemiplimab + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Cemiplimab + Cisplatin + Pemetrexed Disodium lung non-small cell carcinoma sensitive detail...
CD274 positive Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab lung non-small cell carcinoma sensitive detail...
CD274 positive Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab lung non-small cell carcinoma sensitive detail...
CD274 positive Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab lung non-small cell carcinoma sensitive detail...
ATM Q1919P RP-3500 lung non-small cell carcinoma sensitive detail...
ROS1 rearrange Carboplatin + Pembrolizumab + Pemetrexed Disodium lung non-small cell carcinoma predicted - sensitive detail...
ROS1 rearrange Carboplatin + Paclitaxel + Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Surufatinib + Toripalimab-tpzi lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E Lifirafenib + PD-0325901 lung non-small cell carcinoma predicted - sensitive detail...
RET fusion HS-10365 lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E Binimetinib + Encorafenib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Lorlatinib + PF-07284892 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK G1202R Lorlatinib + PF-07284892 lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion Repotrectinib lung non-small cell carcinoma sensitive detail...
CD274 positive AZD2936 lung non-small cell carcinoma predicted - sensitive detail...
ATM Q1331H ATM I1441fs Radiotherapy lung non-small cell carcinoma predicted - sensitive detail...
BRAF G466V IHMT-RAF-128 lung non-small cell carcinoma sensitive detail...
BRAF L597V NRAS Q61K IHMT-RAF-128 lung non-small cell carcinoma sensitive detail...
ROS1 rearrange TQ-B3101 lung non-small cell carcinoma sensitive detail...
ROS1 fusion TQ-B3139 lung non-small cell carcinoma predicted - sensitive detail...
CD274 pos STK11 mut Pembrolizumab lung non-small cell carcinoma not predictive detail...
CD274 pos KEAP1 mut Pembrolizumab lung non-small cell carcinoma not predictive detail...
ALK rearrange TQ-B3139 lung non-small cell carcinoma sensitive detail...
PBRM1 mutant unspecified PD-1 antibody lung non-small cell carcinoma predicted - resistant detail...
PBRM1 mutant unspecified PD-L1 antibody lung non-small cell carcinoma predicted - resistant detail...
BRAF V600X Tunlametinib + Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp IO102-IO103 + Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
ROS1 fusion ROS1 G2032R Repotrectinib lung non-small cell carcinoma predicted - sensitive detail...
RET amp Selpercatinib lung non-small cell carcinoma predicted - sensitive detail...
RET mutant EP0031 lung non-small cell carcinoma predicted - sensitive detail...
BRAF G469A SIJ777 lung non-small cell carcinoma sensitive detail...
BRAF G466V SIJ777 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK T1151M Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK L1152V ALK G1269A Ensartinib lung non-small cell carcinoma predicted - sensitive detail...
ALK E1210K Ensartinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK S1206F Ensartinib lung non-small cell carcinoma predicted - resistant detail...
BRAF L485_P490delinsY LXH 254 lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY Encorafenib lung non-small cell carcinoma decreased response detail...
BRAF L485_P490delinsY Sorafenib lung non-small cell carcinoma sensitive detail...
BRAF L485_P490delinsY Ulixertinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF L485_P490delinsY LXH 254 + Trametinib lung non-small cell carcinoma predicted - sensitive detail...
BRAF L485_P490delinsY Sorafenib + Trametinib lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange Ficonalkib lung non-small cell carcinoma sensitive detail...
EML4 - ALK Afatinib + Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y Afatinib + Lorlatinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F Lorlatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK C1156Y ALK I1171T ALK L1198F Afatinib + Crizotinib lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M ALK D1203N Crizotinib lung non-small cell carcinoma resistant detail...
ALK rearrange ALK G1202R Ficonalkib lung non-small cell carcinoma predicted - sensitive detail...
ATM inact mut Ceralasertib + Durvalumab lung non-small cell carcinoma predicted - sensitive detail...
FGFR2 amp CPL304110 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M ALK G1202R Brigatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK L1196P Lorlatinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK L1198R Crizotinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK C1235R ALK C1237Y Brigatinib lung non-small cell carcinoma predicted - resistant detail...
FGFR2 fusion ABSK061 lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp Necitumumab + Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp PDC*lung01 + Pembrolizumab lung non-small cell carcinoma predicted - sensitive detail...
ATM mutant M1774 lung non-small cell carcinoma predicted - sensitive detail...
CD274 positive Cemiplimab lung non-small cell carcinoma predicted - sensitive detail...
BRAF G469A PF-07799933 lung non-small cell carcinoma sensitive detail...
BRAF G466V PF-07799933 lung non-small cell carcinoma predicted - sensitive detail...
BRAF V600E NRAS Q61K PF-07799933 lung non-small cell carcinoma predicted - sensitive detail...
ALK rearrange ALK L1196M ALK G1202R Brigatinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK P1094H Alectinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK ALK L1196Q Ceritinib lung non-small cell carcinoma predicted - resistant detail...
EML4 - ALK NVL-655 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M NVL-655 lung non-small cell carcinoma sensitive detail...
EML4 - ALK ALK L1196M ALK G1202R Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK T1151M ALK G1202R Crizotinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK L1196M ALK G1202R Ceritinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK T1151M ALK G1202R Ceritinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK L1196M ALK G1202R Alectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK T1151M ALK G1202R Alectinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK T1151M ALK G1202R Brigatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK L1196M ALK G1202R Lorlatinib lung non-small cell carcinoma resistant detail...
EML4 - ALK ALK T1151M ALK G1202R Lorlatinib lung non-small cell carcinoma resistant detail...
BRAF V600X Cobimetinib + Vemurafenib lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion NVL-655 lung non-small cell carcinoma predicted - sensitive detail...
ALK fusion ALK G1202R NVL-655 lung non-small cell carcinoma predicted - sensitive detail...
ATM inact mut RP-3500 lung non-small cell carcinoma predicted - sensitive detail...
CD274 over exp PF-06801591 lung non-small cell carcinoma predicted - sensitive detail...
ROS1 rearrange Foritinib lung non-small cell carcinoma sensitive detail...
RET fusion SY-5007 lung non-small cell carcinoma sensitive detail...
ALK rearrange Deulorlatinib lung non-small cell carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00150657 Phase II Bevacizumab + Carboplatin + Gemcitabine Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer Unknown status USA 0
NCT00254319 Phase II Carboplatin Bevacizumab + Pemetrexed Disodium Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Unknown status USA 0
NCT00313599 Phase I Lapatinib + Paclitaxel Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT00547105 Phase II Erlotinib Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer Completed USA 0
NCT00569296 Phase I Aldesleukin + EGFRBi-armed autologous activated T cells + Sargramostim Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer Terminated USA 0
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) Completed USA | AUS 2
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00828009 Phase II Cyclophosphamide Bevacizumab Paclitaxel Emepepimut-S Carboplatin BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT00932451 Phase II Crizotinib An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Completed USA | SWE | POL | NLD | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | AUS 6
NCT00950365 Phase II Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT00975767 Phase Ib/II Docetaxel + Glesatinib Erlotinib + Glesatinib A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer Terminated USA 0
NCT00978250 Phase II 5-Fluoro-2-deoxycytidine + Tetrahydrouridine A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Completed USA 0
NCT00979212 Phase II Panitumumab Carboplatin + Paclitaxel Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10) Completed USA 0
NCT00996892 Phase I Cobimetinib + Pictilisib Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT00997334 Phase II Erlotinib Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC Completed USA 0
NCT01005797 Phase I Panobinostat + Sorafenib Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Completed USA 0
NCT01014598 Phase I Cisplatin Cisplatin in Treating Patients With Lung Cancer Completed USA 0
NCT01059552 Phase I Vorinostat Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT01061788 Phase I Everolimus + Ganitumab + Panitumumab A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer Completed USA 0
NCT01107626 Phase III Pemetrexed Disodium Bevacizumab Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA | GBR | FRA | ESP 0
NCT01179269 Phase II Paclitaxel + Pazopanib Stage IIIB/IV Non-Small Cell Lung Cancer Withdrawn 0
NCT01210378 Phase II Nitroglycerin Nitroglycerin in Non-small Cell Lung Cancer Terminated NLD 0
NCT01233687 Phase Ib/II Rilotumumab Erlotinib AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT01248247 Phase I Erlotinib MK2206 + Selumetinib Sorafenib Erlotinib + MK2206 BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study Completed USA 0
NCT01263782 Phase II Bevacizumab Carboplatin + Pemetrexed Disodium Cixutumumab BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer Completed USA 0
NCT01288430 Phase I DS-2248 A Study of DS-2248, in Subjects With Advanced Solid Tumors Terminated USA 0
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | CAN | AUS 0
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Completed USA 0
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed USA | ITA | FRA | AUS 1
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Completed USA | CAN 0
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Completed USA | POL | ESP 0
NCT01336634 Phase II Dabrafenib Dabrafenib + Trametinib Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. Completed USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU 3
NCT01336842 Phase I Cisplatin Panobinostat Pemetrexed Disodium Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors Completed USA 0
NCT01344824 Phase II Bevacizumab Erlotinib Carboplatin Pemetrexed Disodium Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers Completed USA 0
NCT01351415 Phase III Bevacizumab A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer Completed USA | SVK | NLD | LBN | ITA | GRC | FRA | ESP | DNK | DEU | BRA | BEL | AUT | ARG 4
NCT01383148 Phase Ib/II MVA-MUC1-IL2 vaccine Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Terminated USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | BEL 0
NCT01386385 Phase Ib/II Carboplatin + Paclitaxel Carboplatin + Etoposide + Veliparib Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed USA 0
NCT01391533 Phase I SAR125844 Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Completed USA | ITA | FRA | ESP 0
NCT01449461 Phase Ib/II Brigatinib A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Completed 0
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Disodium Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Completed USA | CAN 0
NCT01455389 Phase Ib/II Quaratusugene Ozeplasmid Erlotinib Diphenhydramine Dexamethasone FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer Terminated USA 0
NCT01456325 Phase III Erlotinib Onartuzumab A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) Completed USA | POL | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG 10
NCT01465802 Phase II Dacomitinib Alclometasone Doxycycline Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Completed USA 1
NCT01487265 Phase II Buparlisib + Erlotinib Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib Completed USA 0
NCT01493843 Phase II Carboplatin Pictilisib Bevacizumab Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer Completed USA | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG 3
NCT01514864 Phase II Dasatinib Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation Terminated USA | POL | GBR | DEU | CAN | BRA 1
NCT01526928 Phase Ib/II Rociletinib Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients Terminated USA | POL | FRA | AUS 0
NCT01532089 Phase II Bevacizumab Bevacizumab + Erlotinib Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Completed USA 0
NCT01537744 Phase I Azacitidine + Romidepsin A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer Completed USA 0
NCT01545947 Phase I Azacitidine + Onatasertib Erlotinib + Onatasertib Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer Completed USA | ESP 0
NCT01553942 Phase II Afatinib Cisplatin Pemetrexed Disodium Afatinib With CT and RT for EGFR-Mutant NSCLC Active, not recruiting USA 0
NCT01573702 Phase II Erlotinib Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Completed USA 0
NCT01574729 Phase II rAD-p53 Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma Unknown status 1
NCT01578551 Phase II Metformin Carboplatin + Paclitaxel Bevacizumab A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. Terminated USA 0
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA | NLD | GBR | FRA | ESP | AUS 1
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed USA | DNK | CAN 0
NCT01620190 Phase II Nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer Completed USA 0
NCT01621542 Phase I WT2725 Clinical Study of WT2725 in Patients With Advanced Malignancies Completed USA 0
NCT01628471 Phase Ib/II Decitabine + Genistein MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer Completed CAN 0
NCT01630733 Phase III Docetaxel Custirsen + Docetaxel A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Unknown status USA | POL | NZL | ITA | ISR | HUN | ESP | DEU | AUS 6
NCT01639508 Phase II Cabozantinib Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity Recruiting USA 0
NCT01642251 Phase Ib/II Cisplatin + Etoposide Veliparib Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer Completed USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Terminated USA 0
NCT01646125 Phase II Docetaxel Luminespib Pemetrexed Disodium An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Terminated USA | POL | NOR | NLD | ITA | GBR | FRA | ESP 4
NCT01647711 Phase I Afatinib A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations Completed USA 0
NCT01649284 Phase I Afatinib Afatinib Expanded Access Program Approved for marketing USA 0
NCT01649947 Phase II Bevacizumab + Carboplatin + Hydroxychloroquine + Paclitaxel Carboplatin + Hydroxychloroquine + Paclitaxel Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II Completed USA 0
NCT01653470 Phase I Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors Completed USA | CAN | BEL 0
NCT01664754 Phase I Pemetrexed Disodium Carboplatin Exemestane Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer Completed USA 0
NCT01676714 Phase II Dovitinib Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Completed USA 0
NCT01700400 Phase I Carboplatin Everolimus Bevacizumab Pemetrexed Disodium Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer Completed USA 0
NCT01708993 Phase II Docetaxel Pemetrexed Disodium Pelareorep + Pemetrexed Disodium Docetaxel + Pelareorep Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy Completed CAN 0
NCT01712217 Phase Ib/II Crizotinib Onalespib A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Completed USA | FRA | ESP | CAN 1
NCT01717482 Phase II Metformin Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer Terminated USA 0
NCT01720836 Phase Ib/II MUC1 peptide-Poly-ICLC vaccine Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer Recruiting USA 0
NCT01723800 Phase I Buparlisib + Carboplatin + Pemetrexed Disodium PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer Completed USA 0
NCT01725165 Phase II Oligometastatic Disease Completed USA | CAN 0
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Completed USA 0
NCT01746251 Phase II Afatinib Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation Unknown status USA 0
NCT01750281 Phase II Docetaxel Docetaxel + Selumetinib Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. Completed USA | POL | NLD | HUN | FRA | DEU | BRA | BGR 0
NCT01752400 Phase II Luminespib AUY922 for Advanced ALK-positive NSCLC Completed USA 0
NCT01769391 Phase II Necitumumab Carboplatin + Paclitaxel A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer Completed USA | POL | DEU 3
NCT01772797 Phase I Ceritinib Luminespib Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer Completed USA | ITA | ESP | AUS 1
NCT01783197 Phase I Selumetinib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Completed CAN 0
NCT01784640 Phase I Luminespib + Pemetrexed Disodium Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer Completed USA 0
NCT01788566 Phase II Cisplatin + Gemcitabine + Necitumumab A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer Completed USA | NLD | FRA | ESP | CAN 2
NCT01798485 Phase III Ganetespib Docetaxel A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Terminated USA | SVN | ROU | POL | NLD | ITA | HUN | HRV | GBR | FRA | ESP | DEU | CAN | BEL | AUT 5
NCT01801111 Phase II Erlotinib Alectinib A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment Completed USA | SWE | NLD | LUX | ITA | GBR | FRA | ESP | DNK | DEU | BEL | AUS 4
NCT01802632 Phase Ib/II Osimertinib AZD9291 First Time In Patients Ascending Dose Study (AURA) Completed USA | ITA | GBR | FRA | ESP | DEU | AUS 3
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed USA 0
NCT01813734 Phase II Ponatinib Ponatinib in Advanced NSCLC w/ RET Translocations Completed USA 0
NCT01820754 Phase II Cisplatin Ipilimumab Carboplatin Paclitaxel Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT01822496 Phase II Carboplatin + Cisplatin + Erlotinib + Etoposide + Paclitaxel Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer Terminated USA 0
NCT01828112 Phase III Docetaxel Pemetrexed Disodium Ceritinib LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Completed USA | TUR | NLD | LBN | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BEL 6
NCT01829217 Phase II Sunitinib Sunitinib in Never-Smokers With Lung Adenocarcinoma Completed USA 0
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed USA | ESP | CHE 0
NCT01833143 Phase II Bortezomib Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D Completed USA 0
NCT01837329 Phase I Tetrathiomolybdate Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer Completed USA 0
NCT01839955 Phase Ib/II Erlotinib + Quinacrine Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer Completed USA 0
NCT01848756 Phase Ib/II SNX-5422 Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers Terminated USA 0
NCT01851369 Phase Ib/II Temozolomide + TRC102 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas Completed USA 0
NCT01854034 Phase II Luminespib Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR Completed USA 0
NCT01857271 Phase II Erlotinib Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer Terminated USA 0
NCT01858389 Phase II Dacomitinib A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer Completed USA 1
NCT01859026 Phase I Binimetinib + Erlotinib A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation Completed USA 0
NCT01866410 Phase II Cabozantinib + Erlotinib Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer Completed USA 0
NCT01868022 Phase I Docetaxel Cisplatin + Pemetrexed Disodium GSK3052230 Carboplatin + Paclitaxel Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Completed USA | NLD | GBR | ESP | DNK | BEL 1
NCT01871805 Phase Ib/II Alectinib A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Completed USA | CAN 0
NCT01884285 Phase I AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib AZD8186 First Time In Patient Ascending Dose Study Completed USA | GBR | ESP | CAN 0
NCT01887886 Phase III Erlotinib + Onartuzumab A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation Completed USA | FRA | ESP | DEU 4
NCT01892046 Phase I Carboplatin SNX-5422 Paclitaxel Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors Completed USA 0
NCT01900652 Phase II Emibetuzumab + Erlotinib Emibetuzumab A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants Completed USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | BEL 1
NCT01903993 Phase II Atezolizumab A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" Completed USA | TUR | SWE | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL 2
NCT01911325 Phase Ib/II Buparlisib Docetaxel Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Terminated USA | SWE | ITA | FRA | ESP | DEU | BEL 1
NCT01911507 Phase I Capmatinib + Erlotinib INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer Completed USA 0
NCT01912625 Phase I Carboplatin + Paclitaxel + Trametinib Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Terminated USA 0
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed USA | ITA | GBR | ESP | CAN 0
NCT01928160 Phase II Erlotinib + Pemetrexed Disodium Pemetrexed Disodium Carboplatin Carboplatin + Erlotinib Cisplatin Cisplatin + Erlotinib Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib Withdrawn 0
NCT01928576 Phase II Nivolumab Entinostat Azacitidine Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. Completed USA 0
NCT01933932 Phase III Docetaxel + Selumetinib Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1) Active, not recruiting USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG 6
NCT01935947 Phase II Gemcitabine Azacitidine + Entinostat Docetaxel + Irinotecan + Pemetrexed Disodium Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Terminated USA 0
NCT01946789 Phase I Nogapendekin alfa inbakicept A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Completed USA 0
NCT01947608 Phase I Ceritinib Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC No longer available USA | ARG 8
NCT01951690 Phase II Defactinib Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Completed USA 0
NCT01957007 Phase I Docetaxel + Vantictumab A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC Completed USA 0
NCT01966003 Phase III Bevacizumab Bevacizumab-awwb Carboplatin + Paclitaxel Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer Completed USA | BGR | AUS 0
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA | NLD | AUS 0
NCT01967095 Phase I Erlotinib Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer Completed USA 0
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Active, not recruiting USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | AUT | AUS 1
NCT01970865 Phase II Lorlatinib Crizotinib A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations Completed USA | ITA | FRA | ESP | DEU | CHE | CAN | BEL | AUS 5
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn USA 0
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed USA | FRA | ESP | DEU | CHE 2
NCT01988896 Phase I Atezolizumab + Cobimetinib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | DEU | CAN | AUS 2
NCT01993810 Phase III Carboplatin + Pemetrexed Disodium Durvalumab Cisplatin + Etoposide Carboplatin + Paclitaxel Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Active, not recruiting USA 0
NCT01998126 Phase I Erlotinib + Ipilimumab Crizotinib + Ipilimumab Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts Completed USA 0
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed USA 0
NCT01999985 Phase I Afatinib + Dasatinib Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02000947 Phase Ib/II Durvalumab + Tremelimumab A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer Completed USA | ITA | GBR | FRA | ESP | BEL | AUS 2
NCT02004106 Phase I Cergutuzumab amunaleukin A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed USA | NLD | GBR | FRA | FIN | ESP | DNK | CHE 0
NCT02008227 Phase III Docetaxel Atezolizumab A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK Completed USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | AUT | ARG 11
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Completed USA 0
NCT02013219 Phase I Alectinib + Atezolizumab Atezolizumab + Erlotinib A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer Completed USA | GBR | FRA | ESP 2
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed USA 0
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed USA 0
NCT02019979 Phase II Metformin Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO) Terminated USA 0
NCT02022982 Phase Ib/II Palbociclib + PD-0325901 PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors Completed USA 0
NCT02031458 Phase II Atezolizumab A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH Completed USA | TUR | SVN | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BGR | BEL | AUS 5
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn USA 0
NCT02039674 Phase Ib/II Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pemetrexed Disodium Ipilimumab + Pembrolizumab Erlotinib + Pembrolizumab Gefitinib + Pembrolizumab A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021) Completed 0
NCT02041533 Phase III Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed USA | TUR | SWE | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 4
NCT02043665 Phase I Coxsackievirus A21 Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) Completed USA | GBR | AUS 0
NCT02044601 Phase Ib/II Carboplatin + Onartuzumab + Paclitaxel Carboplatin + Erlotinib + Onartuzumab + Paclitaxel Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) Withdrawn USA 0
NCT02045446 Phase II Bevacizumab + Erlotinib Docetaxel + Gemcitabine Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02047344 Phase II Antroquinonol Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC Completed USA 1
NCT02066636 Phase III Nivolumab A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153) Completed USA | CAN 0
NCT02071862 Phase I Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Completed USA 0
NCT02075840 Phase III Alectinib Crizotinib A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (ALEX) Active, not recruiting USA | TUR | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BRA | AUS 16
NCT02079636 Phase I LY3023414 Abemaciclib Gemcitabine Pemetrexed Disodium Ramucirumab A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Completed USA | ESP 0
NCT02080078 Phase I Erlotinib + Theophylline A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline Terminated CAN 0
NCT02085070 Phase II Pembrolizumab MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Completed USA 0
NCT02087176 Phase II Adavosertib Pegfilgrastim A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer Terminated USA 0
NCT02087241 Phase II Adavosertib Carboplatin + Pemetrexed Disodium Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer Terminated USA 0
NCT02087423 Phase II Durvalumab A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC) Active, not recruiting USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT 6
NCT02088112 Phase I Durvalumab + Gefitinib MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). Completed USA 2
NCT02091999 Phase I Enfortumab vedotin-ejfv A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Completed USA | CAN 0
NCT02094573 Phase II Brigatinib A Phase 2, Multicenter, Randomized Study of AP26113 Completed 0
NCT02106546 Phase III Veliparib Carboplatin + Paclitaxel Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Completed USA | TUR | SWE | SVK | POL | NZL | NOR | NLD | LVA | LTU | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | EST | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUT | AUS 9
NCT02108964 Phase Ib/II Nazartinib A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies Completed USA | NLD | ESP | DEU | CAN 4
NCT02109016 Phase II Lucitanib A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer Terminated USA | ITA | FRA | ESP | DEU 0
NCT02113813 Phase I Naquotinib A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations Completed USA 0
NCT02115464 Phase II Metformin Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy Terminated CAN 0
NCT02117024 Phase II Cyclophosphamide + HS-110 Pemetrexed Disodium Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Terminated USA 0
NCT02119650 Phase II Cisplatin + Pemetrexed Disodium + Ruxolitinib Cisplatin + Pemetrexed Disodium Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer Terminated USA 0
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed 1
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed USA 0
NCT02125461 Phase III Durvalumab A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) Completed USA | TUR | SVK | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT02132598 Phase II Cabozantinib Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases Terminated USA 0
NCT02133196 Phase II Aldesleukin + Cyclophosphamide + Fludarabine T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Recruiting USA 0
NCT02134015 Phase III Erlotinib Erlotinib + Patritumab Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) Terminated USA | POL | ITA | HUN | GBR | ESP | DEU | CZE | CAN | BEL 0
NCT02134886 Phase I Erlotinib Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection Terminated USA 0
NCT02134912 Phase II Crizotinib + Pemetrexed Disodium Pemetrexed Disodium S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Terminated USA 0
NCT02142738 Phase III Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Completed 0
NCT02143466 Phase I Osimertinib + Savolitinib Osimertinib + Selumetinib Durvalumab + Osimertinib AZD9291 in Combination With Ascending Doses of Novel Therapeutics Active, not recruiting USA | POL | CAN 5
NCT02147990 Phase II Rociletinib TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) Terminated USA | NLD | GBR | FRA | ESP | DEU | CHE | CAN | AUS 3
NCT02151981 Phase III Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Osimertinib AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3) Completed USA | SWE | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | AUS 7
NCT02152631 Phase III Erlotinib Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) Active, not recruiting USA | TUR | ROU | POL | ITA | ISR | GRC | FRA | ESP | DEU | CAN | BRA | AUT | ARG 7
NCT02157792 Phase I Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine M6620 First in Human Study Completed USA | GBR 0
NCT02157883 Phase I Osimertinib Itraconazole + Osimertinib Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) Completed USA | NLD | GBR | BEL 2
NCT02163733 Phase I Osimertinib Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer Completed GBR | FRA | ESP 1
NCT02168777 Phase Ib/II Refametinib + Regorafenib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated USA 0
NCT02174172 Phase I Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | NLD 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02179671 Phase II Docetaxel + Selumetinib Gefitinib Durvalumab Osimertinib Tremelimumab Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed USA 0
NCT02183883 Phase II Afatinib Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity (DARWIN1) Completed GBR 0
NCT02186301 Phase II Rociletinib Erlotinib TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy Terminated USA | ITA | ESP | DEU 3
NCT02186847 Phase II Metformin Carboplatin + Paclitaxel Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Active, not recruiting USA | ISR | CAN 0
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Terminated USA | FRA | ESP | CAN 1
NCT02192541 Phase I Aflibercept + Ganetespib Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas Terminated USA 0
NCT02193152 Phase I Pazopanib Pazopanib in Molecularly Selected Patients With Advanced NSCLC Terminated USA 0
NCT02193282 Phase III Erlotinib Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Active, not recruiting USA 1
NCT02194738 Phase I Nivolumab Crizotinib Erlotinib Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting USA 2
NCT02197234 Phase I Osimertinib + Simvastatin Simvastatin Osimertinib Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC Completed USA | FRA | ESP | BEL 1
NCT02197247 Phase I Osimertinib + Rifampin Osimertinib Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC Completed USA | NLD | GBR | ESP 2
NCT02201992 Phase III Crizotinib Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Recruiting USA 2
NCT02206763 Phase I Erlotinib + Momelotinib Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT02220894 Phase III Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) Completed 0
NCT02221739 Phase II Ipilimumab Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02222922 Phase I Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Completed USA | ESP 0
NCT02225405 Phase I Cisplatin + Docetaxel + Nintedanib Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC) Completed USA 0
NCT02228369 Phase I Osimertinib AZD3759 Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM) Completed USA | AUS 2
NCT02250326 Phase II Azacitidine + Nab-paclitaxel Nab-paclitaxel Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN 0
NCT02257619 Phase II Docetaxel Itacitinib Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer Terminated USA 0
NCT02258607 Phase I Momelotinib Momelotinib + Trametinib Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase Terminated USA 0
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed 0
NCT02259582 Phase II Carboplatin + Pemetrexed Disodium Demcizumab A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer Completed USA | ITA | ESP | BEL | AUS 0
NCT02259621 Phase II Nivolumab Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC Active, not recruiting USA | CAN 0
NCT02264678 Phase Ib/II Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS 1
NCT02264990 Phase III Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers Completed USA | TUR | NZL | NLD | ISR | HUN | GBR | FIN | ESP | DNK | DEU | CZE | CAN | AUS | ARG 5
NCT02271139 Phase III Alectinib Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib No longer available USA 0
NCT02271906 Phase II Afatinib The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting Terminated USA 0
NCT02272413 Phase III Carboplatin + Paclitaxel Bevacizumab Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer Completed USA | TUR | ROU | POL | ITA | HUN | HRV | GRC | GBR | ESP | DEU | BRA | BGR | ARG 14
NCT02273375 Phase III Durvalumab Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC Active, not recruiting USA | ROU | POL | NZL | NLD | ITA | HUN | FRA | ESP | CAN | BRA | BGR | AUS 6
NCT02277457 Phase I Crizotinib Erlotinib Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations Withdrawn USA 0
NCT02279433 Phase I Taletrectinib A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Completed USA 0
NCT02281409 Phase Ib/II Mogamulizumab Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Completed USA 0
NCT02283320 Phase II Docetaxel A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer Completed USA 1
NCT02289833 Phase II Ado-trastuzumab emtansine A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed USA | POL | ITA | ESP | DEU | CHE 1
NCT02292550 Phase Ib/II Ceritinib + Ribociclib Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. Completed USA | ITA | FRA | ESP 2
NCT02296125 Phase III Erlotinib Osimertinib Gefitinib AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA) Active, not recruiting USA | TUR | SWE | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUS 11
NCT02298153 Phase I Atezolizumab + Epacadostat A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Terminated USA 0
NCT02299141 Phase I Nintedanib Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT02299505 Phase I Ceritinib Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) Completed USA | TUR | POL | NLD | LBN | ITA | GRC | GBR | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS 7
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Completed USA 0
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Completed USA | ITA | ISR | FRA | ESP | CAN | BEL | AUT | AUS 0
NCT02309177 Phase I Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer Completed USA 0
NCT02309892 Phase I Carboplatin + L-DOS47 + Pemetrexed Disodium A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC Terminated USA 0
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Completed 1
NCT02314364 Phase II A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC Completed USA 0
NCT02314481 Phase II Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII) Active, not recruiting GBR 0
NCT02315066 Phase I PF-04518600 PF-04518600 + Utomilumab Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 Completed USA | NLD | FRA 1
NCT02316002 Phase II Pembrolizumab Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer Completed USA 0
NCT02317016 Phase I Osimertinib Rosuvastatin Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer Completed USA | GBR | FRA | ESP 0
NCT02318368 Phase II Erlotinib Erlotinib + Ficlatuzumab A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label Terminated USA | ITA | AUS 4
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Completed USA 0
NCT02321293 Phase I Erlotinib + Gefitinib A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC Unknown status CAN 0
NCT02321501 Phase I Ceritinib + Everolimus Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02321540 Phase Ib/II Ibrutinib A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer Completed USA 0
NCT02322281 Phase III Pemetrexed Disodium Gemcitabine Paclitaxel Docetaxel Rociletinib TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy Terminated USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS 2
NCT02323126 Phase II Nazartinib + Nivolumab Capmatinib + Nivolumab Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer Terminated USA | ITA | FRA | ESP | DEU | CHE | AUS 1
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA | GBR 0
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed USA 0
NCT02335944 Phase Ib/II Capmatinib + Nazartinib Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. Terminated USA | NOR | ITA | FRA | ESP | DEU | CAN | AUS 3
NCT02336451 Phase II Ceritinib A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges Completed USA | TUR | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS 5
NCT02337530 Phase II Selumetinib Cisplatin + Pemetrexed Disodium Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer Completed CAN 0
NCT02342353 Phase Ib/II Erlotinib + Pacritinib Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) Terminated USA 0
NCT02343952 Phase II Pembrolizumab Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC Completed USA 0
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated USA | ISR 0
NCT02349633 Phase II Avelumab + Mavelertinib Mavelertinib + Palbociclib Mavelertinib Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) Terminated USA | AUS 2
NCT02350764 Phase II Ipilimumab + Nivolumab Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs Completed USA 0
NCT02352948 Phase III Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) Completed USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUS 9
NCT02355431 Phase II Erlotinib Itacitinib INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations Withdrawn USA 0
NCT02357836 Phase I Itraconazole Neoadjuvant Itraconazole in Non-small Cell Lung Cancer Completed USA 0
NCT02364609 Phase I Afatinib + Pembrolizumab Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib Completed USA 0
NCT02364999 Phase III Bevacizumab + Carboplatin + Paclitaxel A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC Completed USA | TUR | ROU | POL | NLD | ITA | HUN | HRV | GRC | FRA | ESP | DEU | CZE | BRA | BGR | AUS 11
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated USA | ESP 0
NCT02366143 Phase III Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Nab-paclitaxel Atezolizumab + Carboplatin + Paclitaxel TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Completed USA | SVK | NLD | LVA | LTU | ITA | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG 9
NCT02367781 Phase III Atezolizumab Carboplatin + Nab-paclitaxel A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer Completed USA | ITA | ISR | FRA | ESP | DEU | CAN | BEL 0
NCT02367794 Phase III Carboplatin Nab-paclitaxel Paclitaxel Atezolizumab A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Completed USA | SVK | NLD | LVA | LTU | ITA | ISR | FRA | ESP | DEU | CAN | BRA | BGR | BEL | AUT | AUS | ARG 9
NCT02381314 Phase I Ipilimumab + MGA271 Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer Completed USA 0
NCT02382406 Phase Ib/II Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC Terminated USA 0
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Terminated USA 0
NCT02387216 Phase II Seribantumab Pemetrexed Disodium Docetaxel A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC Terminated USA | HUN | FRA | ESP | DEU | CAN 0
NCT02391480 Phase I Mivebresib A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Completed USA 0
NCT02392507 Phase II Carboplatin + Nab-paclitaxel + Necitumumab A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC Completed USA 0
NCT02393625 Phase I Ceritinib + Nivolumab Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer Active, not recruiting USA | ITA | ESP | CAN | BEL | AUS 2
NCT02395172 Phase III Avelumab Docetaxel Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) Completed USA | TUR | SVK | ROU | POL | ITA | ISR | HUN | HRV | GBR | FRA | ESP | DNK | CZE | CHE | BRA | BGR | BEL | AUS | ARG 9
NCT02400814 Phase I Atezolizumab MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer Terminated USA 0
NCT02403193 Phase Ib/II Spartalizumab + Taminadenant Taminadenant Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO) Completed USA 0
NCT02403271 Phase Ib/II Durvalumab + Ibrutinib A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors Completed USA 0
NCT02404441 Phase Ib/II Spartalizumab Phase I/II Study of PDR001 in Patients With Advanced Malignancies Completed USA | TUR | POL | NOR | NLD | LBN | ITA | HUN | FRA | ESP | DEU | CAN 2
NCT02407171 Phase Ib/II Pembrolizumab Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC Completed USA 0
NCT02409342 Phase III Atezolizumab Carboplatin Pemetrexed Disodium Cisplatin A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Completed USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | BRA 7
NCT02409355 Phase III Carboplatin Cisplatin Gemcitabine Atezolizumab A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Terminated USA | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE 3
NCT02411448 Phase III Erlotinib Gefitinib + Ramucirumab Erlotinib + Ramucirumab Osimertinib + Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY) Active, not recruiting USA | TUR | ROU | ITA | GRC | GBR | FRA | ESP | DEU | CAN 4
NCT02412371 Phase II Veliparib Carboplatin + Paclitaxel A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer Terminated USA 0
NCT02414139 Phase II Capmatinib Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1) Completed USA | SWE | NOR | NLD | LBN | ITA | ISR | GBR | FRA | ESP | DEU | BEL | AUT | ARG 6
NCT02414269 Phase I Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Active, not recruiting USA 0
NCT02422381 Phase Ib/II Gemcitabine Pembrolizumab MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT02422589 Phase I Warfarin Midazolam Ceritinib A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors Completed USA | ITA | ESP | DNK 0
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Completed USA | ESP 0
NCT02424617 Phase Ib/II Bemcentinib + Erlotinib A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer Completed USA 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02435121 Phase II SAR125844 A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification Completed BEL 0
NCT02437136 Phase Ib/II Entinostat + Pembrolizumab Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma Completed USA 0
NCT02438722 Phase II Afatinib Afatinib + Cetuximab S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02439450 Phase I HS-110 Nivolumab A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Completed USA 0
NCT02443324 Phase I Pembrolizumab + Ramucirumab A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium Completed USA | GBR | FRA | ESP | DEU 1
NCT02444741 Phase Ib/II Pembrolizumab MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT02448251 Phase I Abivertinib Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer Terminated USA | FRA | ESP 0
NCT02448303 Phase II Acalabrutinib Pembrolizumab Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer Completed USA 0
NCT02450539 Phase II Abemaciclib Docetaxel A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Completed USA | ROU | POL | ITA | HUN | FRA | ESP | DEU | AUS 4
NCT02451852 Phase I Osimertinib AZD9291 US Expanded Access Program No longer available USA 0
NCT02451865 Phase I Binimetinib + Docetaxel Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer Withdrawn USA 0
NCT02451930 Phase I Necitumumab Pembrolizumab A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC Completed USA | FRA | ESP 1
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated USA 0
NCT02453282 Phase III Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) Active, not recruiting USA | NLD | ITA | HUN | FRA | ESP | DEU | CHE | CAN | BEL | AUS 6
NCT02454842 Phase II TH-4000 Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC Terminated USA | AUS 0
NCT02454933 Phase III Osimertinib Durvalumab Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL) Completed CAN 2
NCT02460224 Phase Ib/II Ieramilimab Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT02460367 Phase Ib/II Docetaxel + Indoximod Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer Terminated USA 0
NCT02463994 Phase I Atezolizumab A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC Completed USA 0
NCT02468661 Phase I Capmatinib Capmatinib + Erlotinib Erlotinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification Terminated USA | NLD | ITA | FRA | ESP | DEU | BEL 3
NCT02469701 Phase II Nivolumab BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease Terminated USA 0
NCT02471846 Phase I Navoximod Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02474355 Phase III Osimertinib Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Completed SWE | ITA | IRL | GBR | ESP | DNK | CAN | BRA | BEL | AUT | AUS | ARG 4
NCT02475213 Phase I MGA271 + Pembrolizumab Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer Completed USA 0
NCT02475382 Expanded access Nivolumab Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169) No longer available CAN | BRA 0
NCT02477826 Phase III Nivolumab Cisplatin Ipilimumab Pemetrexed Disodium Carboplatin Gemcitabine An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed USA | ROU | POL | NLD | LBN | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 10
NCT02485652 Phase II Olmutinib Phase II Trial of HM61713 for the Treatment of >= 2nd Line T790M Mutation Positive Adenocarcinoma of the Lung Terminated USA | ITA | ESP | DEU | CAN | AUS 4
NCT02486718 Phase III Atezolizumab Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer Active, not recruiting USA | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS 8
NCT02487095 Phase Ib/II Berzosertib Topotecan Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer Active, not recruiting USA 0
NCT02489903 Phase II Etoposide RRx-001 Carboplatin Cisplatin Nab-paclitaxel RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens Completed USA 0
NCT02492867 Phase 0 Durvalumab Carboplatin + Paclitaxel A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT02495636 Phase II Atezolizumab + Rasdegafusp alfa Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer Withdrawn USA 0
NCT02496663 Phase I Necitumumab + Osimertinib Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor Active, not recruiting USA 0
NCT02498613 Phase II Cediranib + Olaparib A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed USA 0
NCT02500199 Phase I Pyrotinib Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Unknown status USA 0
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Completed USA | NOR | ESP 0
NCT02503722 Phase I Osimertinib + Sapanisertib Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT02504372 Phase III Pembrolizumab Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) Active, not recruiting 0
NCT02504489 Phase III Docetaxel Docetaxel + Plinabulin Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3) Completed USA | AUS 1
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Completed USA | POL | ESP | DEU | CHE | BEL | AUT | AUS 1
NCT02511106 Phase III Osimertinib AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA) Active, not recruiting USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | HUN | FRA | ESP | DEU | CAN | BRA | BEL | AUS 9
NCT02511184 Phase I Crizotinib Pembrolizumab Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients Terminated USA 0
NCT02514174 FDA approved Afatinib Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Completed USA 0
NCT02516813 Phase I Peposertib Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy Completed USA | SWE | NOR | NLD | DNK | DEU | CHE | BEL 0
NCT02520778 Phase I Navitoclax + Osimertinib Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Completed USA 0
NCT02521051 Phase Ib/II Bevacizumab Alectinib Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Unknown status USA 0
NCT02523469 Phase Ib/II Nivolumab + Nogapendekin alfa inbakicept ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer Completed USA 0
NCT02525757 Phase II Atezolizumab Carboplatin + Paclitaxel MPDL3280A With Chemoradiation for Lung Cancer Active, not recruiting USA 0
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed USA 0
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | NLD | FRA | CAN 0
NCT02535338 Phase Ib/II Erlotinib + Onalespib Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02537561 Phase I Talazoparib Cisplatin + Gemcitabine Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors Withdrawn 0
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA | FRA 0
NCT02542293 Phase III Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab + Tremelimumab Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE) Active, not recruiting USA | TUR | SWE | ROU | POL | ISR | GRC | GBR | FIN | DNK | BRA | BGR | ARG 16
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated USA 0
NCT02544633 Phase II Glesatinib Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET Completed USA | POL | ITA | HUN | GBR | CAN | AUS 2
NCT02546986 Phase II Azacitidine + Pembrolizumab Pembrolizumab Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer Active, not recruiting USA | ITA | GRC | FRA | ESP | DEU 0
NCT02547675 Phase I Rociletinib Rociletinib (CO-1686) USA Expanded Access Program No longer available USA 0
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Terminated USA | POL | GBR | FRA | CAN | AUS 2
NCT02563548 Phase I PEGPH20 + Pembrolizumab Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab Completed USA 0
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 6
NCT02572687 Phase I Durvalumab + Ramucirumab A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Completed USA | ITA | ISR | FRA | ESP | DEU 2
NCT02573259 Phase I PF-06801591 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Completed USA | POL | BGR 4
NCT02574078 Phase Ib/II Crizotinib + Nivolumab Erlotinib + Nivolumab Nivolumab + Pemetrexed Disodium Bevacizumab Carboplatin + Pemetrexed Disodium Bevacizumab + Nivolumab Nivolumab Erlotinib Carboplatin + Paclitaxel Carboplatin + Docetaxel Carboplatin + Nab-paclitaxel Carboplatin + Gemcitabine Paclitaxel Docetaxel Pemetrexed Disodium Gemcitabine A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370) Completed USA 0
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed FRA | ESP | DNK 0
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Active, not recruiting USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG 9
NCT02576574 Phase III Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin Avelumab in First-line NSCLC (JAVELIN Lung 100) Completed USA | TUR | SVK | ROU | POL | NZL | NLD | LTU | LBN | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | EST | ESP | DNK | DEU | CZE | CYP | CAN | BRA | BGR | BEL | AUS 14
NCT02576665 Phase I Toca FC + Vocimagene amiretrorepvec A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Terminated USA 0
NCT02578680 Phase III Carboplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) Completed 0
NCT02580708 Phase Ib/II Trametinib Rociletinib A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT02581787 Phase Ib/II Fresolimumab SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer Completed USA 0
NCT02581943 Phase II Paclitaxel Pembrolizumab Carboplatin Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Completed USA 0
NCT02584634 Phase I Crizotinib Avelumab Lorlatinib Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) Terminated USA | ESP | AUS 2
NCT02588261 Phase III Naquotinib Gefitinib Erlotinib A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations Terminated USA | ROU | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS 11
NCT02589522 Phase I Berzosertib VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT02591615 Phase II Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC Completed USA 0
NCT02592577 Phase I MAGE A10c796T for Advanced NSCLC Completed USA | GBR | ESP | CAN 0
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Completed USA 0
NCT02595944 Phase III Nivolumab Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) Active, not recruiting USA 0
NCT02599454 Phase I Atezolizumab Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02605746 Phase I Ceritinib Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis Completed USA 0
NCT02608268 Phase Ib/II Spartalizumab Sabatolimab Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Terminated USA | NLD | ITA | CHE | CAN 4
NCT02608385 Phase I Pembrolizumab Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors Active, not recruiting USA 0
NCT02609776 Phase I Amivantamab-vmjw Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Lazertinib Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS) Active, not recruiting USA | GBR | FRA | ESP | CAN | AUS 4
NCT02616393 Phase II Tesevatinib Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases Completed USA 0
NCT02621398 Phase I Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN | AUS 0
NCT02630186 Phase Ib/II Atezolizumab + Rociletinib A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC Terminated USA 0
NCT02635061 Phase I Citarinostat + Ipilimumab + Nivolumab Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer Terminated USA 0
NCT02637531 Phase I Pembrolizumab Eganelisib A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Unknown status USA 0
NCT02638090 Phase Ib/II Pembrolizumab Vorinostat Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Completed USA 0
NCT02639091 Phase I Anetumab ravtansine + Cisplatin + Pemetrexed Disodium Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors Completed USA | ITA 0
NCT02639234 Phase II FANG vaccine + Nivolumab Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer Withdrawn USA 0
NCT02640508 Phase II Eribulin + Lenvatinib Eribulin and Lenvatinib in Advanced Solid Tumors Completed USA 0
NCT02642042 Phase II Docetaxel + Trametinib Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02642939 Phase II Mifepristone Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Terminated USA 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT02648724 Phase Ib/II SYM015 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies Completed USA | ESP | DNK 3
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated USA 0
NCT02654587 Phase III OSE 2101 Pemetrexed Disodium Docetaxel Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1) Terminated USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE 0
NCT02658097 Phase II Pembrolizumab A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC Completed USA 0
NCT02659059 Phase II Ipilimumab + Nivolumab Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568) Completed USA | CAN 0
NCT02664181 Phase II Nivolumab Decitabine + Nivolumab + Tetrahydrouridine Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE) Completed USA 0
NCT02665416 Phase I RO5520985 + Selicrelumab Bevacizumab + Selicrelumab Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors Completed USA | NLD | ITA | ESP | DNK | CAN | BEL 0
NCT02666105 Phase II Exemestane Exemestane in Post-Menopausal Women With NSCLC Completed USA 0
NCT02669914 Phase II Durvalumab MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Terminated USA 0
NCT02671955 Phase I Onvatilimab A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated USA 0
NCT02681549 Phase II Bevacizumab + Pembrolizumab Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02684461 Phase II Pembrolizumab Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel Completed USA 0
NCT02695290 Phase III Afatinib Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) Terminated USA 0
NCT02696993 Phase Ib/II Nivolumab Ipilimumab + Nivolumab Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT02698176 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) Terminated 0
NCT02706392 Phase I Cyclophosphamide + Fludarabine + ROR1 CAR-T cells Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Terminated USA 0
NCT02706626 Phase II Brigatinib Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors Terminated USA 0
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Terminated USA 0
NCT02713529 Phase Ib/II AMG 820 + Pembrolizumab Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer Completed USA | ESP | DEU | CAN | BEL | AUS 0
NCT02713828 Phase Ib/II Glembatumumab vedotin Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Terminated USA 0
NCT02713867 Phase III Nivolumab A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384) Completed USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS 0
NCT02715284 Phase I Dostarlimab-gxly A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) Recruiting USA | POL | ITA | GBR | FRA | ESP | DNK | CZE | CAN | BRA | ARG 2
NCT02716038 Phase II Atezolizumab + Carboplatin + Nab-paclitaxel Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC Completed USA 0
NCT02716116 Phase Ib/II Mobocertinib A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer Active, not recruiting USA | ITA | GBR | ESP | DEU 5
NCT02718066 Phase Ib/II Chidamide + Nivolumab Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer Completed USA 0
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Completed USA | NLD | ITA | FRA | ESP | CAN | AUS 2
NCT02730247 Phase II Nab-paclitaxel + Ramucirumab Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02733250 Phase Ib/II Nab-paclitaxel + Pembrolizumab Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001) Completed CAN 0
NCT02737501 Phase III Brigatinib Crizotinib ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L) Completed USA | SWE | NOR | NLD | LUX | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | AUT | AUS 4
NCT02740985 Phase I AZD4635 AZD4635 + Durvalumab A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies Completed USA 0
NCT02750215 Phase II Capmatinib A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Completed USA 0
NCT02750514 Phase II Dasatinib + Nivolumab Nivolumab + Relatlimab Nivolumab Linrodostat + Nivolumab An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung) Terminated USA | ITA | FRA | ESP | CHE | CAN | AUT | AUS 0
NCT02767804 Phase III Crizotinib Ensartinib eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG 4
NCT02768558 Phase III Cisplatin + Etoposide Cisplatin + Etoposide + Nivolumab Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC Terminated USA 0
NCT02770014 Phase II Erlotinib Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer Terminated USA 0
NCT02775435 Phase III Carboplatin + Nab-paclitaxel Pembrolizumab Carboplatin + Paclitaxel A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Completed 0
NCT02779751 Phase II Abemaciclib + Pembrolizumab A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Active, not recruiting USA | TUR | ITA | FRA | ESP | BEL 1
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Completed USA | NLD | FRA | CAN 0
NCT02784158 Phase I Brigatinib An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer No longer available USA 0
NCT02789345 Phase I Osimertinib + Ramucirumab Necitumumab + Osimertinib A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer Completed USA | FRA | ESP 2
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed USA 0
NCT02803203 Phase Ib/II Bevacizumab + Osimertinib Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers Completed USA 0
NCT02805660 Phase Ib/II Durvalumab + Mocetinostat Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC Terminated USA 0
NCT02812667 Phase I Nivolumab + Plinabulin Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT02817633 Phase I Cobolimab Cobolimab + Dostarlimab-gxly + TSR-033 Cisplatin + Cobolimab + Dostarlimab-gxly + Pemetrexed Disodium Cobolimab + Dostarlimab-gxly Cobolimab + Nivolumab Cobolimab + Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) Recruiting USA | ESP 2
NCT02818426 Phase Ib/II UCPVax Universal Cancer Peptide-based Vaccination in Metastatic NSCLC (UCPVax) Completed FRA 0
NCT02818920 Phase II Pembrolizumab Neoadjuvant Pembrolizumab Active, not recruiting USA 0
NCT02823990 Phase II MVA-MUC1-IL2 vaccine + Nivolumab TG4010 and Nivolumab in Patients With Lung Cancer Completed USA 0
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | NLD | FRA | ESP | BEL | AUS 0
NCT02826161 Phase III Napabucasin + Paclitaxel Paclitaxel A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L) Terminated USA 0
NCT02829099 Phase I JNJ-64457107 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Completed ISR | ESP 0
NCT02831491 Phase II Docetaxel + Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer Withdrawn 0
NCT02831933 Phase II AdV-tk + Nivolumab Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN) Terminated USA 0
NCT02834247 Phase I Mivavotinib + Nivolumab A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Terminated USA | ITA | GBR | ESP 0
NCT02835833 Phase I Bevacizumab + Nintedanib Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Completed USA 0
NCT02840994 Phase Ib/II CV301 + Nivolumab Nivolumab A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer Completed USA 0
NCT02846792 Phase Ib/II Nivolumab + Plinabulin Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer Terminated USA 0
NCT02848651 Phase II Atezolizumab A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST] Completed USA 0
NCT02855125 Phase II Tegafur-gimeracil-oteracil Potassium TAS-114 + Tegafur-gimeracil-oteracil Potassium A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 Completed USA | POL | ITA | FRA | ESP 1
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Completed USA | FRA | AUS 1
NCT02858869 Phase 0 Pembrolizumab Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Completed USA 0
NCT02860780 Phase I Prexasertib + Ralimetinib A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Completed USA | DEU 0
NCT02864251 Phase III Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Pemetrexed Disodium A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722) Completed USA | FRA | ESP | CAN 6
NCT02869789 Phase III Ipilimumab + Nivolumab A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Completed USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | ARG 3
NCT02879617 Phase II Durvalumab A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients Completed USA 0
NCT02879760 Phase Ib/II Ad-MAGEA3 + MG1-MAGEA3 + Pembrolizumab Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients Completed CAN 0
NCT02879994 Phase II Pembrolizumab Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Terminated USA 0
NCT02888743 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT02890069 Phase I LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Completed USA | NLD | GBR | ESP | DEU 2
NCT02897375 Phase I Cisplatin + Palbociclib Carboplatin + Palbociclib Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Completed USA 0
NCT02897765 Phase I Nivolumab NEO-PV-01 + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Completed USA 0
NCT02898116 Phase Ib/II Durvalumab + Ensartinib Ensartinib A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer Completed USA 0
NCT02900664 Phase I Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) Completed USA | ITA | ISR | FRA | ESP | CAN | BEL 2
NCT02904954 Phase II Durvalumab Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer Completed USA 0
NCT02912949 Phase Ib/II Zenocutuzumab A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting USA | SWE | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT 4
NCT02917993 Phase Ib/II Itacitinib + Osimertinib An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Active, not recruiting USA | ESP 2
NCT02919449 Phase I Atezolizumab + MV-NIS Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer Terminated USA 0
NCT02920450 Phase Ib/II Carboplatin + Gedatolisib + Paclitaxel Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) Terminated USA 0
NCT02920996 Phase II Merestinib Merestinib In Non-Small Cell Lung Cancer And Solid Tumors Terminated USA 0
NCT02922764 Phase I RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Active, not recruiting USA 0
NCT02922777 Phase I Bemcentinib + Docetaxel Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. Completed USA 0
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP | CHE 0
NCT02926768 Phase Ib/II CK-101 Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Completed USA | POL | NZL | AUS 1
NCT02927301 Phase II Atezolizumab A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02927340 Phase II Lorlatinib A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions Unknown status USA 0
NCT02941601 Phase II Carboplatin + Gemcitabine + Necitumumab A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Withdrawn USA | ROU | ITA | GBR | DEU | BEL 1
NCT02942095 Phase I Erlotinib + Ixazomib Study of Ixazomib and Erlotinib in Solid Tumors Completed USA 0
NCT02944396 Phase II Carboplatin + Paclitaxel + Pemetrexed Disodium + Veliparib Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Veliparib Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) Completed USA 0
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Completed USA | ITA | DEU | CHE | CAN | AUT 3
NCT02947386 Phase Ib/II Nimotuzumab + Nivolumab Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer Completed USA 0
NCT02949843 Phase II Nivolumab + Pembrolizumab Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations Terminated USA 0
NCT02950038 Phase II Ibrutinib + Nivolumab Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Withdrawn 0
NCT02952248 Phase I Ezabenlimab A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Completed USA | GBR | CAN 0
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Completed USA 0
NCT02952989 Phase I SGN-2FF A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Terminated USA 0
NCT02954523 Phase Ib/II Dasatinib + Osimertinib Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations Terminated USA 0
NCT02954991 Phase II Nivolumab + Sitravatinib Mocetinostat + Nivolumab Glesatinib + Nivolumab Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer Terminated USA 0
NCT02955290 Phase Ib/II CIMAvax-EGF + Nivolumab CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Recruiting USA 0
NCT02955758 Phase II Pembrolizumab Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Completed USA 0
NCT02959437 Phase Ib/II Azacitidine + Epacadostat + Pembrolizumab Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Terminated USA | GBR | ESP 0
NCT02963610 Phase Ib/II Lenalidomide + Pembrolizumab Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Terminated USA 0
NCT02965885 Phase I Pimitespib A Study of TAS-116 in Patients With Solid Tumors Completed USA | ITA | GBR 0
NCT02967133 Phase II Nab-paclitaxel + Nivolumab Nivolumab A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Terminated USA 0
NCT02971501 Phase II Osimertinib Bevacizumab + Osimertinib Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases Active, not recruiting USA 0
NCT02974725 Phase I LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma Terminated USA | SWE | POL | ITA | ISR | FRA | ESP | DEU | BEL | AUS 1
NCT02978404 Phase II Nivolumab Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases Completed CAN 0
NCT02981108 Phase Ib/II Aumolertinib A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC Unknown status USA 0
NCT02983045 Phase Ib/II Nivolumab + NKTR-214 A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) Completed USA | POL | ITA | GBR | FRA | ESP | CAN | BEL 0
NCT02983578 Phase II Danvatirsen + Durvalumab AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer Active, not recruiting USA 0
NCT02987998 Phase I Cisplatin + Etoposide + Pembrolizumab Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC Terminated USA 0
NCT02991651 Phase I Erlotinib + IRX4204 Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC Suspended USA 0
NCT02992912 Phase II Atezolizumab Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) Active, not recruiting FRA 0
NCT02994576 Phase II Atezolizumab Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer (PRINCEPS) Completed FRA 0
NCT02998528 Phase III Ipilimumab + Nivolumab Carboplatin + Cisplatin + Docetaxel + Gemcitabine + Pemetrexed Disodium + Vinorelbine A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816) Active, not recruiting USA | TUR | ROU | ITA | HUN | GRC | FRA | ESP | CAN | BRA | ARG 4
NCT02998567 Phase I Guadecitabine + Pembrolizumab Decitabine and Cedazuridine + Pembrolizumab Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (HyPeR) Recruiting GBR 0
NCT03001882 Phase II Ipilimumab + Nivolumab An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Completed USA | ROU | NLD | ITA | FRA | ESP | DEU | BEL 0
NCT03003468 Phase Ib/II Pembrolizumab + PGG beta-glucan Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 Completed USA 0
NCT03003962 Phase III Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) Active, not recruiting USA | TUR | POL | NLD | HUN | AUS 6
NCT03004105 Phase II Durvalumab + Selumetinib MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) Withdrawn 0
NCT03004183 Phase II Pembrolizumab AdV-tk + Valacyclovir SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STOMP) Completed USA 0
NCT03014648 Phase II Atezolizumab Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Completed USA 0
NCT03023319 Phase I Bosutinib + Pemetrexed Disodium Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Completed USA 0
NCT03023423 Phase Ib/II Atezolizumab + Daratumumab Atezolizumab A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX) Completed USA | POL | HUN | FRA | ESP 0
NCT03023904 Phase II Nivolumab Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads Withdrawn 0
NCT03037385 Phase Ib/II Pralsetinib Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL 5
NCT03041181 Phase II Docetaxel + Nivolumab Docetaxel Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab Terminated USA 0
NCT03042013 Phase II Naquotinib A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study Withdrawn 0
NCT03048136 Phase III Ipilimumab + Nivolumab A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955) Withdrawn USA | DEU | CAN | ARG 1
NCT03048500 Phase II Metformin + Nivolumab Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Unknown status USA 0
NCT03049618 Phase II Pembrolizumab + sEphB4-HSA Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Active, not recruiting USA 0
NCT03050060 Phase II Nelfinavir + Nivolumab Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer Terminated USA 0
NCT03050554 Phase Ib/II Avelumab Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT03052608 Phase III Lorlatinib Crizotinib A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC Active, not recruiting USA | TUR | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | ARG 9
NCT03054038 Phase I Afatinib + Necitumumab Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer Terminated USA 0
NCT03057106 Phase II Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC Active, not recruiting CAN | AUS 0
NCT03064854 Phase I Canakinumab + Cisplatin + Pemetrexed Disodium + Spartalizumab Canakinumab + Carboplatin + Spartalizumab Carboplatin + Paclitaxel + Spartalizumab Cisplatin + Pemetrexed Disodium + Spartalizumab Cisplatin + Gemcitabine + Spartalizumab PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients Terminated USA | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BEL 3
NCT03066206 Phase II Poziotinib Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Active, not recruiting USA 0
NCT03071757 Phase I ABBV-368 ABBV-368 + Nivolumab A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 3
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03082300 Phase I Naquotinib A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations Terminated USA 0
NCT03083808 Phase II Gemcitabine + Pembrolizumab Docetaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Phase II Trial of Continuation Therapy in Advanced NSCLC Completed USA 0
NCT03086733 Phase II Metformin Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore) Completed CAN 0
NCT03087448 Phase Ib/II Ceritinib + Trametinib Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT03087760 Phase II Pembrolizumab Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer Completed USA 0
NCT03088930 Phase II Crizotinib Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer Completed USA 0
NCT03090737 Phase II Nivolumab Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907) Completed USA | ROU | CAN 2
NCT03093116 Phase Ib/II Repotrectinib A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Recruiting USA | POL | NLD | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS 7
NCT03095612 Phase Ib/II Docetaxel + Selinexor Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT03098550 Phase Ib/II Daratumumab + Nivolumab A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread Completed USA | ITA | FRA | ESP | DEU | CHE | CAN | AUS 1
NCT03099174 Phase I Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. Completed USA | FRA | FIN | ESP | DNK 2
NCT03101839 Phase I AZD4785 Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Completed USA | GBR 0
NCT03102242 Phase II Atezolizumab Atezolizumab Immunotherapy in Patients With Advanced NSCLC Completed USA 0
NCT03102606 Phase II Plinabulin Pegfilgrastim Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Completed USA 3
NCT03110978 Phase II Nivolumab Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR Active, not recruiting USA 0
NCT03121417 Phase II Nivolumab Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer Withdrawn USA 0
NCT03122717 Phase I Gefitinib + Osimertinib Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Active, not recruiting USA 0
NCT03123783 Phase Ib/II Nivolumab + Sotigalimab CD40 Agonistic Antibody APX005M in Combination With Nivolumab Completed USA | ESP 0
NCT03130764 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC Withdrawn 0
NCT03131037 Phase I AdV-tk + Valacyclovir Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03131206 Phase Ib/II Alectinib A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Terminated USA 0
NCT03132922 Phase I afamitresgene autoleucel MAGE-A4c1032T for Multi-Tumor Active, not recruiting USA | CAN 0
NCT03137771 Phase II Docetaxel Pemetrexed Disodium Gemcitabine Erlotinib Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Active, not recruiting USA | ISR | CAN 1
NCT03138889 Phase Ib/II NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors Terminated USA | FRA | ESP | DEU | AUS 0
NCT03141359 Phase II Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC Active, not recruiting USA 0
NCT03148327 Phase Ib/II Durvalumab Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy Active, not recruiting USA | AUS 0
NCT03156114 Phase I Ezabenlimab Miptenalimab This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. Completed USA | POL | GBR | ESP | CAN 0
NCT03157128 Phase Ib/II Selpercatinib A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) Active, not recruiting USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | AUS 5
NCT03158129 Phase II Nivolumab Ipilimumab + Nivolumab Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection Active, not recruiting USA 0
NCT03158883 Phase I Avelumab UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients Completed USA 0
NCT03164616 Phase III Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) Active, not recruiting USA | POL | HUN | GBR | DEU | BRA | BGR 12
NCT03164772 Phase Ib/II BI 1361849 + Durvalumab + Tremelimumab Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC Completed USA 0
NCT03166254 Phase I Pembrolizumab Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer Withdrawn 0
NCT03166631 Phase I BI 891065 + Ezabenlimab BI 891065 A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Terminated USA 0
NCT03168464 Phase Ib/II Nivolumab Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) Terminated USA 0
NCT03170206 Phase Ib/II Palbociclib Binimetinib Binimetinib + Palbociclib Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03175224 Phase Ib/II Vebreltinib APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) Recruiting USA | ITA | HUN | GBR | FRA | FIN | ESP | CAN | AUS 4
NCT03177291 Phase I Carboplatin + Pemetrexed Disodium + Pirfenidone Carboplatin + Paclitaxel + Pirfenidone Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Active, not recruiting USA 0
NCT03178071 Expanded access Lorlatinib Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations No longer available USA 0
NCT03178552 Phase II Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Divarasib Atezolizumab + Cobimetinib + Vemurafenib Alectinib A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) Active, not recruiting USA | TUR | POL | NZL | ITA | ISR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG 14
NCT03179436 Phase Ib/II MK-1308 + Pembrolizumab MK-1308 Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) Completed USA | SWE | POL | NZL | ITA | ISR | GRC | FRA | ESP | CAN | AUS 5
NCT03181308 Phase I Carotuximab + Nivolumab Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC Completed USA 0
NCT03184571 Phase II Bemcentinib + Pembrolizumab BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC Completed USA | NOR | GBR | ESP 0
NCT03191149 Phase II Osimertinib Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change Recruiting USA 0
NCT03191786 Phase III Atezolizumab Gemcitabine Vinorelbine A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) Completed SVK | ROU | POL | LUX | ITA | IRL | GBR | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BGR | BEL | ARG 7
NCT03195491 Phase III Nivolumab A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (CheckMate870) Completed 2
NCT03197467 Phase II Pembrolizumab Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN) Completed DEU 0
NCT03202940 Phase Ib/II Alectinib + Cobimetinib A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC Active, not recruiting USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting POL | NZL | FRA | ESP | AUS 4
NCT03215706 Phase III Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) Completed USA | ROU | POL | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG 5
NCT03215810 Phase I Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT03217071 Phase II Pembrolizumab Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer Completed USA 0
NCT03217669 Phase I Epacadostat + Sirolimus Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy Active, not recruiting USA 0
NCT03220477 Phase I Guadecitabine + Mocetinostat + Pembrolizumab Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. Active, not recruiting USA 0
NCT03223155 Phase I Ipilimumab + Nivolumab Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03224871 Phase I Pembrolizumab Aldesleukin Nivolumab A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC. Completed USA 0
NCT03225664 Phase Ib/II Pembrolizumab Pembrolizumab + Trametinib BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT03228186 Phase II Docetaxel + MLN4924 Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Terminated USA 0
NCT03228667 Phase II Nivolumab + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept + Pembrolizumab QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy Recruiting USA 0
NCT03232892 Phase II Trametinib Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer Terminated USA 0
NCT03233724 Phase Ib/II Pembrolizumab Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas Terminated USA 0
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Active, not recruiting USA 0
NCT03237377 Phase II Durvalumab + Tremelimumab Durvalumab Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT03239340 Phase III Osimertinib A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (ELIOS) Completed USA | ITA | ESP 2
NCT03242915 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab in Combination With Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Targetable Genetic Alterations, Previously Treated With Appropriate Targeted Agents, With Progressive Disease Active, not recruiting USA 0
NCT03247309 Phase I Aldesleukin + IMA201 Cyclophosphamide + Fludarabine TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) Completed USA | DEU 0
NCT03255083 Phase I DS-1205c + Osimertinib DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Terminated 1
NCT03256136 Phase II Carboplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer Completed USA 0
NCT03257722 Phase Ib/II Idelalisib + Pembrolizumab Pembrolizumab + Idelalisib for Lung Cancer Study Terminated USA 0
NCT03260491 Phase I Patritumab deruxtecan U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer Recruiting USA | NLD | ESP 3
NCT03262779 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. Completed USA 0
NCT03265080 Phase I ADXS-NEO Expressing Personalized Tumor Antigens Study Terminated USA 0
NCT03268057 Phase Ib/II Avelumab + Pepinemab VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer Completed USA 0
NCT03270176 Phase I Avelumab + Xevinapant A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy Completed ROU | POL | CAN 0
NCT03274479 Phase I PBF-1129 PBF-1129 in Patients With NSCLC Active, not recruiting USA 0
NCT03275597 Phase I Durvalumab + Tremelimumab Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition Terminated USA 0
NCT03285321 Phase II Ipilimumab + Nivolumab Nivolumab Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA 0
NCT03285763 FDA approved Atezolizumab A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (TAIL) Completed SWE | SVN | POL | NLD | LVA | LBN | ITA | GRC | GBR | ESP | DNK | BRA | ARG 11
NCT03286296 Phase I LZM009 LZM009 to Treat Patients With Advanced Solid Tumors Completed USA 0
NCT03289962 Phase I Autogene cevumeran Atezolizumab + Autogene cevumeran A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Active, not recruiting USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL 0
NCT03292133 Phase II Gefitinib + Nazartinib A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03299088 Phase I Pembrolizumab + Trametinib Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Active, not recruiting USA 0
NCT03302234 Phase III Pembrolizumab Ipilimumab + Pembrolizumab Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) Completed USA | TUR | POL | LVA | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG 9
NCT03302247 Phase II Nivolumab Gemcitabine + Nivolumab Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy Terminated USA 0
NCT03307759 Phase I Pembrolizumab Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq) Completed CAN | AUS 0
NCT03308942 Phase II Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Completed USA 0
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Terminated USA | CAN 0
NCT03311672 Phase II Pembrolizumab T-Cell PET Imaging With [18F]F-AraG in Lung Cancer Withdrawn 0
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) Recruiting USA | GBR | AUS 1
NCT03313804 Phase II Pembrolizumab Atezolizumab Nivolumab Priming Immunotherapy in Advanced Disease With Radiation Active, not recruiting USA 0
NCT03317496 Phase II Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies Terminated USA | ITA | HUN | GBR | ESP | CZE | CAN | AUS 0
NCT03318939 Phase II Poziotinib Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation Terminated USA | NLD | ITA | ISR | FRA | ESP | CAN | BEL 0
NCT03319628 Phase I XMT-1536 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b Active, not recruiting USA 0
NCT03322540 Phase II Pembrolizumab Epacadostat + Pembrolizumab Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) Completed USA | TUR | POL | ITA | ISR | IRL | GBR | EST | ESP | DNK | CHE | CAN | AUS 5
NCT03322566 Phase II Carboplatin + Paclitaxel + Pembrolizumab Epacadostat + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) Completed USA | TUR | ITA | ISR | IRL | HUN | GBR | ESP | CAN | AUS 4
NCT03325166 Phase II Pembrolizumab Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases Terminated USA 0
NCT03326752 Phase I DV281 Phase 1b Dose Escalation and Dose Expansion Trial Completed USA 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Completed USA 0
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Terminated USA | HUN | GBR | DNK | CAN | BEL | AUS 2
NCT03333343 Phase I LXH 254 + Nazartinib Nazartinib + Trametinib Gefitinib + Nazartinib Nazartinib + Ribociclib Capmatinib + Nazartinib Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC Active, not recruiting ITA | DEU | CAN 3
NCT03334617 Phase II Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON) Active, not recruiting USA | ISR | FRA | ESP | DEU | CAN | AUT 1
NCT03337698 Phase Ib/II Atezolizumab + Carboplatin + Gemcitabine Atezolizumab + Ciforadenant Atezolizumab Atezolizumab + Docetaxel Docetaxel Atezolizumab + Cobimetinib Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + RO6958688 A Study Evaluating ThA Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus Lung) Active, not recruiting USA | ISR | GBR | FRA | ESP | AUS 2
NCT03343613 Phase I LY3300054 + LY3381916 LY3381916 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors Terminated USA | ITA | FRA | ESP | DNK | BEL 0
NCT03345810 Phase II Gemcitabine + Vinorelbine Carboplatin + Nab-paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Durvalumab + Gemcitabine + Vinorelbine Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (DURATION) Completed DEU 0
NCT03348904 Phase III Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer Terminated USA 0
NCT03353675 Phase II MVA-MUC1-IL2 vaccine + Nivolumab A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Completed USA | HUN | FRA | BEL 0
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated USA 0
NCT03366766 Phase II Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed USA 0
NCT03367819 Phase Ib/II Isatuximab Cemiplimab + Isatuximab Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies Terminated USA | ITA | GBR | FRA 1
NCT03371992 Phase I Nivolumab Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC (NO3DEXPL) Unknown status USA 0
NCT03377023 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nintedanib + Nivolumab Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer Active, not recruiting USA 0
NCT03379441 Phase II Pembrolizumab Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC (MP-LALC) Unknown status ITA 0
NCT03380871 Phase I Carboplatin + NEO-PV-01 + Pembrolizumab + Pemetrexed Disodium + Poly ICLC A Personalized Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer Completed USA 0
NCT03381274 Phase Ib/II AZD4635 + Oleclumab Oleclumab + Osimertinib Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study Active, not recruiting USA 2
NCT03382899 Phase II Pegilodecakin + Pembrolizumab Pembrolizumab Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 1)mall Cell Lung Cancer (Cypress 1) Terminated USA 0
NCT03382912 Phase II Nivolumab + Pegilodecakin Nivolumab Study of AM0010 With NivolumabStudy of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 2) Terminated USA 0
NCT03383302 Phase Ib/II Nivolumab SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects (STILE) Active, not recruiting GBR 0
NCT03386929 Phase Ib/II Avelumab + Axitinib + Palbociclib Survival Prolongation by Rationale Innovative Genomics (SPRING) Terminated USA | LUX | ISR | ESP 0
NCT03387111 Phase Ib/II Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab Nogapendekin alfa inbakicept Fluorouracil ETBX-011 Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy Terminated USA 0
NCT03391869 Phase III Ipilimumab + Nivolumab Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Recruiting USA 0
NCT03392246 Phase II Osimertinib + Selumetinib A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Active, not recruiting USA 0
NCT03396211 Phase I Nivolumab + Rivoceranib Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Completed USA 0
NCT03396497 Phase I LYC-55716 + Pembrolizumab Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer Unknown status USA 0
NCT03401385 Phase I Datopotamab deruxtecan First-in-human Study of DS-1062a for Advanced Solid Tumors Active, not recruiting USA 1
NCT03409458 Phase Ib/II Avelumab + Imifoplatin A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Completed USA | CHE 0
NCT03410043 Phase II Osimertinib Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study Active, not recruiting USA 0
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Terminated USA | GBR | FRA | ESP 0
NCT03412877 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Recruiting USA 0
NCT03415126 Phase I ERAS-007 A Study of ASN007 in Patients With Advanced Solid Tumors Completed USA 0
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Terminated USA 0
NCT03417037 Phase III Linrodostat + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer Withdrawn USA | TUR | ITA | GRC | FRA | ESP | DEU | CZE | CHE | CAN | BRA | AUT | AUS 4
NCT03417882 Phase II GRN-1201 + Pembrolizumab GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC Terminated USA 0
NCT03418532 Phase Ib/II MP0250 MP0250 DARPin Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC Terminated USA 0
NCT03419559 Phase II LN-145 Durvalumab + LN-145 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer Withdrawn USA 0
NCT03425006 Phase II Itacitinib + Pembrolizumab Pembrolizumab and Itacitinib (INCB039110) for NSCLC Terminated USA 0
NCT03425279 Phase Ib/II Mecbotamab Vedotin CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors Active, not recruiting USA 2
NCT03425331 Phase II Ipilimumab + Nivolumab Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC Terminated USA 0
NCT03425643 Phase III Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Active, not recruiting USA | ROU | POL | LVA | LTU | ITA | IRL | GBR | FRA | EST | ESP | DEU | CAN | BRA | BEL | AUS | ARG 8
NCT03430063 Phase II Cemiplimab + Ipilimumab Cemiplimab A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer Terminated USA | POL | GBR | FRA | ESP | DEU | BEL 2
NCT03433469 Phase II Osimertinib Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery Active, not recruiting USA 0
NCT03434418 Phase II Osimertinib A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations Completed USA 0
NCT03435250 Phase I AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss Terminated USA | FRA | ESP 0
NCT03438318 Phase I Atezolizumab + Vidutolimod Study Evaluating CMP-001 in Combination With Atezolizumab in Subjects With Non-Small Cell Lung Cancer Completed USA 0
NCT03446417 Phase I ZN-e4 A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer Completed USA 1
NCT03446547 Phase II Durvalumab Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID) Recruiting SWE | NOR | FIN 0
NCT03447769 Phase III Canakinumab Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None) Terminated USA | TUR | SVN | ROU | POL | NOR | LBN | ITA | ISR | ISL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | AUT | ARG 18
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab Ciforadenant + CPI-006 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Completed USA | AUS 0
NCT03455556 Phase Ib/II Anetumab ravtansine + Atezolizumab Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer Terminated USA 0
NCT03455829 Phase Ib/II Osimertinib G1T38 + Osimertinib G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Completed USA 0
NCT03456063 Phase III Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium Atezolizumab + Carboplatin + Cisplatin + Nab-paclitaxel + Pemetrexed Disodium A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) Active, not recruiting USA | SWE | SVN | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CHE | BRA | AUT | AUS 9
NCT03456076 Phase III Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer Active, not recruiting USA | TUR | ROU | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | AUT | AUS 12
NCT03468985 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer Completed USA 0
NCT03469960 Phase III Ipilimumab + Nivolumab Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE) Active, not recruiting FRA 0
NCT03472560 Phase II Avelumab + Axitinib A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) Terminated USA | POL | ITA | HUN | ESP 3
NCT03473925 Phase II Navarixin + Pembrolizumab Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Completed USA | ISR | CAN | AUS 1
NCT03474497 Phase Ib/II Aldesleukin + Pembrolizumab + Radiotherapy Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade Recruiting USA 0
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03485209 Phase II Tisotumab vedotin-tftv Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 1
NCT03497767 Phase II Osimertinib A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN) Completed AUS 1
NCT03502330 Phase I Cabiralizumab + Nivolumab + Sotigalimab Cabiralizumab + Sotigalimab APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Completed USA 0
NCT03504488 Phase Ib/II BA3021 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors Completed USA | POL | GRC | ESP 2
NCT03505710 Phase II Trastuzumab deruxtecan DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (DESTINY-Lung01) Completed USA | NLD | FRA | ESP 1
NCT03509012 Phase I Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Etoposide Cisplatin + Durvalumab Carboplatin + Durvalumab + Paclitaxel Carboplatin + Cisplatin + Durvalumab + Etoposide Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) Completed USA | ESP 3
NCT03515629 Phase III Cemiplimab + Ipilimumab Pembrolizumab REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer Terminated USA | LTU | ITA 0
NCT03515837 Phase III Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Cisplatin + Pemetrexed Disodium Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) Completed USA | SWE | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS 6
NCT03516214 Phase I Nazartinib + Trametinib EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations (EATON) Completed ESP | DEU 0
NCT03516981 Phase II MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) Active, not recruiting USA | POL | ITA | IRL | GBR | ESP | CHE | CAN | AUS 7
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03520686 Phase III Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. Active, not recruiting USA 0
NCT03520842 Phase II Methotrexate + Regorafenib Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Completed USA 0
NCT03521154 Phase III Osimertinib A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA) Active, not recruiting USA | TUR | HUN | ESP | BRA | ARG 11
NCT03525795 Phase Ib/II CPI-1205 + Ipilimumab ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors Completed USA 0
NCT03526887 Phase II Pembrolizumab Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay) Completed ESP 0
NCT03527108 Phase II Nivolumab + Ramucirumab Nivolumab Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Recruiting USA 0
NCT03535363 Phase I Osimertinib Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC Completed USA 0
NCT03535740 Phase II Brigatinib A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2) Completed USA | SWE | NLD | ITA | FRA | ESP | DEU | CAN | AUT | AUS 5
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03539536 Phase II Telisotuzumab vedotin Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer Active, not recruiting USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BGR | BEL | AUS 6
NCT03546361 Phase I Ad-CCL21-DC Ad-CCL21-DC + Pembrolizumab CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03559049 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03563716 Phase II Atezolizumab + Tiragolumab Atezolizumab A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Active, not recruiting USA | FRA | ESP 3
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Completed USA | ITA | GBR | ESP | CAN 4
NCT03567642 Phase I Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers Active, not recruiting USA 0
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Completed USA 0
NCT03568656 Phase Ib/II Atezolizumab + CCS1477 CCS1477 CCS1477 + Olaparib CCS1477 + Darolutamide Abiraterone + CCS1477 CCS1477 + Enzalutamide Study to Evaluate CCS1477 in Advanced Tumours Recruiting USA | SWE | NLD | GBR | FRA | ESP 0
NCT03573947 Phase II Ipilimumab + Nivolumab + Paclitaxel Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (TOP1705) Completed USA 0
NCT03574220 Phase I Pembrolizumab Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer Withdrawn 0
NCT03574649 Phase II Carboplatin + Cisplatin + Docetaxel + Paclitaxel Aldoxorubicin + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Nogapendekin alfa inbakicept + Paclitaxel QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Withdrawn USA 0
NCT03580694 Phase I Cemiplimab + REGN4659 Cemiplimab Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT03581487 Phase Ib/II Durvalumab + Selumetinib + Tremelimumab Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03583086 Phase Ib/II Nivolumab + Vorolanib H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Completed USA 0
NCT03586453 Phase II Osimertinib Osimertinib In EGFR Mutant Lung Cancer Active, not recruiting USA 0
NCT03588039 Phase I Oraxol + Pembrolizumab Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT03589547 Phase II Durvalumab Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung Active, not recruiting USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Completed USA 0
NCT03595059 Phase I Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors Active, not recruiting USA | NLD | ISR | ESP | CAN | AUS 4
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03596866 Phase III Brigatinib Alectinib A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3) Completed USA | SWE | ROU | ITA | HRV | GRC | FRA | ESP | DEU | CAN | AUT | ARG 8
NCT03600701 Phase II Atezolizumab + Cobimetinib Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT03608020 Phase Ib/II BMX-001 A Trial for Treatment